Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | ERN1 | O75460 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28615862 | 0.92 | TDP1 (0.53) | TDP1ERN1HSD17B10PTPN1HDAC3 | |
| SCHEMBL14774600 | 0.86 | TDP1 (0.52) | TDP1ERN1PTPN1HDAC3HDAC4 | |
| SCHEMBL14774601 | 0.86 | TDP1 (0.52) | TDP1ERN1PTPN1HDAC3HDAC4 | |
| SCHEMBL42333 | 0.84 | ERN1 (0.59) | TDP1ERN1HSD17B10PTPN1LMNA | |
| SCHEMBL29958016 | 0.84 | ERN1 (0.59) | TDP1ERN1HSD17B10PTPN1LMNA | |
| SCHEMBL4552823 | 0.84 | TDP1 (0.48) | TDP1ERN1HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL21676102 | 0.79 | TDP1 (0.44) | TDP1ERN1HDAC3HDAC4HDAC1 | |
| SCHEMBL28336792 | 0.79 | TDP1 (0.53) | TDP1ERN1HSD17B10PTPN1MAPT | |
| SCHEMBL16599459 | 0.79 | TDP1 (0.44) | TDP1ERN1HDAC3HDAC4HDAC1 | |
| SCHEMBL24512757 | 0.79 | TDP1 (0.44) | TDP1ERN1HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1124 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114671747-B | Synthesis method of 4-chloro-2-fluorobenzaldehyde | 浙江永太科技股份有限公司 | 2024-10-29 | — | — | CN | claimed |
| US-20240033318-A1 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | OHIO STATE INNOVATION FOUNDATION | 2024-02-01 | — | — | US | claimed |
| CN-114716382-B | Continuous flow synthesis process of Ensifelvir intermediate of anti-new crown drug | 拓信达(启东)医药生物科技有限公司 | 2023-10-27 | — | — | CN | claimed |
| US-11576946-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | OHIO STATE INNOVATION FOUNDATION (US) | 2023-02-14 | — | — | US | claimed |
| CN-115557895-A | Pyrazole derivative and preparation method and application thereof | 贵州大学 | 2023-01-03 | — | — | CN | claimed |
| CN-114716382-A | Continuous flow synthesis process of anti-neocoronal drug Ensittrelvir intermediate | 拓信达(启东)医药生物科技有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-114671747-A | Synthesis method of 4-chloro-2-fluorobenzaldehyde | 浙江永太科技股份有限公司 | 2022-06-28 | — | — | CN | claimed |
| CN-114605328-A | Preparation method of 6-chloro-2-methyl-2H-indazole-5-amine | 汉瑞药业(荆门)有限公司 | 2022-06-10 | — | — | CN | claimed |
| US-20210169966-A1 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | OHIO STATE INNOVATION FOUNDATION | 2021-06-10 | — | — | US | claimed |
| EP-3749365-A2 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | Ohio State Innovation Foundation (US) | 2020-12-16 | — | — | EP | claimed |
| US-RE48335-E1 | Polymyxin derivatives as antimicrobial compounds | MONASH UNIVERSITY (AU) | 2020-12-01 | — | — | US | claimed |
| CN-109651375-B | Tetrahydroquinazoline derivative and synthesis method and application thereof | 上海应用技术大学 | 2020-10-09 | — | — | CN | claimed |
| CN-106414480-B | Polymyxin derivatives as antimicrobial compounds | 莫纳什大学 | 2020-08-04 | — | — | CN | claimed |
| WO-2019148194-A2 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | OHIO STATE INNOVATION FOUNDATION (US) | 2019-08-01 | — | — | WO | claimed |
| US-10017684-B2 | Method and compositions for hydraulic fracturing and for tracing formation water | SPECTRUM TRACER SERVICES, LLC (US) | 2018-07-10 | — | — | US | claimed |
| US-20170306217-A1 | METHOD AND COMPOSITIONS FOR HYDRAULIC FRACTURING AND FOR TRACING FORMATION WATER | NCS Multistage, LLC | 2017-10-26 | — | — | US | claimed |
| US-20170137469-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2017-05-18 | — | — | US | claimed |
| EP-3126376-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | Monash University (AU) | 2017-02-08 | — | — | EP | claimed |
| WO-2015149131-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2015-10-08 | — | — | WO | claimed |
| CN-122029171-A | Small molecule inhibitors of KRAS proteins | 默沙东有限责任公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4732838-A2 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2026-04-29 | — | — | EP | disclosed |
| US-12605451-B2 | Targeted plasma protein degradation | NOVARTIS AG (CH) | 2026-04-21 | — | — | US | disclosed |
| US-12605358-B2 | Composition for preventing or treating nervous system diseases comprising compound that inhibits mTOR signaling pathway as active ingredient | ALIAD BIOPHARMA (KR) | 2026-04-21 | — | — | US | disclosed |
| EP-4725484-A2 | CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2026-04-15 | — | — | EP | disclosed |
| EP-4455140-B1 | CRYSTALLINE FORMS OF A GLP-1 RECEPTOR AGONIST AND PREPARATION METHODS THEREFOR | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2026-04-01 | — | — | EP | disclosed |
| EP-4455141-B1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF A GLP-1 RECEPTOR AGONIST FOR THE TREATMENT OF DIABETES | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2026-03-25 | — | — | EP | disclosed |
| EP-4709371-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4706757-A2 | 2-(((2,3-DIHYDROBENZO[B][1,4]DIOXAN-5-YL)PIPERIDIN-1-YL)METHYL)-1-((OXETAN-2-YL)METHYL)-1H-BENZO[D]IMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS GLP-1 MODULATORS FOR THE TREATMENT OF DIABETES | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-12552791-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260035386-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4209490-B1 | 2-(((2,3-DIHYDROBENZO[B][1,4]DIOXAN-5-YL)PIPERIDIN-1-YL)METHYL)-1-((OXETAN-2-YL)METHYL)-1H-BENZO[D]IMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS GLP-1 MODULATORS FOR THE TREATMENT OF DIABETES | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4660194-A1 | SALT AND CRYSTAL FORM OF CYCLOALKENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2025-12-10 | — | — | EP | disclosed |
| US-12473279-B2 | Fused imidazole derivative, preparation method therefor, and medical use thereof | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| WO-2025235740-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250346599-A1 | TRICYCLIC PHTHALAZINONE PARP INHIBITORS AND METHODS OF USE | VALO HEALTH INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12466840-B2 | Small molecule inhibitors of KRAS proteins | MERCK SHARP & DOHME LLC (US) | 2025-11-11 | — | — | US | disclosed |
| US-12459937-B2 | Fused imidazole derivative, preparation method therefor, and medical use thereof | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-11-04 | — | — | US | disclosed |
| EP-4143183-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4192831-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-14 | — | — | US | disclosed |
| EP-4615847-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250282773-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-09-11 | — | — | US | disclosed |
| US-20250243195-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| US-20250214999-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2025-07-03 | — | — | US | disclosed |
| CN-115720578-B | And tricyclic derivatives, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025122545-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250179083-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2025-06-05 | — | — | US | disclosed |
| CN-119954797-A | Condensed imidazole derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2025-05-08 | — | — | US | disclosed |
| CN-119930605-A | Condensed imidazole derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119930603-A | Condensed imidazole derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250136615-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC | 2025-05-01 | — | — | US | disclosed |
| WO-2025085748-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC (US) | 2025-04-24 | — | — | WO | disclosed |
| US-12281108-B2 | Pyrrolidinone derivatives as formyl peptide 2 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-22 | — | — | US | disclosed |
| CN-119855590-A | Tricyclic phthalazinone PARP inhibitors and methods of use | 瓦罗健康有限公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-4536216-A1 | TRICYCLIC PHTHALAZINONE PARP INHIBITORS AND METHODS OF USE | Valo Health, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-3936192-B1 | PYRROLOPYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| US-12240830-B2 | Fused ring heteroaryl compounds and use thereof | BISICHEM CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-12240855-B2 | Pyrrolopyrazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-03-04 | — | — | US | disclosed |
| US-12227499-B2 | Fused imidazole derivative, preparation method therefor, and medical use thereof | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-02-18 | — | — | US | disclosed |
| US-12227482-B2 | Compounds and compositions for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-18 | — | — | US | disclosed |
| US-20250049777-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-02-13 | — | — | US | disclosed |
| US-20250049778-A1 | CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2025-02-13 | — | — | US | disclosed |
| US-12215103-B2 | — | — | 2025-02-04 | — | — | US | disclosed |
| CN-119330949-A | Polycyclic compound and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-119343339-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-115884969-B | Condensed imidazole derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-113166114-B | Cyclic tetramer compounds as inhibitors of proprotein convertase subtilisin/KEXIN type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240425505-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-12-26 | — | — | US | disclosed |
| EP-4469444-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-3634404-B1 | PYRAZOLE MAGL INHIBITORS | H LUNDBECK AS (DK) | 2024-11-20 | — | — | EP | disclosed |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240376061-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2024233776-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME LLC (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-116003324-B | Synthesis method of 6-chloro-2-methyl-2H-indazole-5-amine | 杭州澳赛诺医药技术有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-116003324-B | Synthesis method of 6-chloro-2-methyl-2H-indazole-5-amine | 杭州澳赛诺医药技术有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20240360109-A1 | CYCLOALKENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2024-10-31 | — | — | US | disclosed |
| EP-4455140-A1 | CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-10-30 | — | — | EP | disclosed |
| EP-4455141-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-10-30 | — | — | EP | disclosed |
| CN-114671747-B | Synthesis method of 4-chloro-2-fluorobenzaldehyde | 浙江永太科技股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-114671747-B | Synthesis method of 4-chloro-2-fluorobenzaldehyde | 浙江永太科技股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-114671747-B | Synthesis method of 4-chloro-2-fluorobenzaldehyde | 浙江永太科技股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-12110290-B2 | Triazolopyridinyl compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240327383-A1 | PIPERIDINE DERIVATIVE, AND PHARMACEUTIAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Yichang Humanwell Pharmaceutical Co., Ltd. (CN) | 2024-10-03 | — | — | US | disclosed |
| CN-116496270-B | 4-Aminopiperidine derivative and preparation method and application thereof | 四川大学华西医院 | 2024-09-24 | — | — | CN | disclosed |
| US-12071404-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2024-08-27 | — | — | US | disclosed |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-08-15 | — | — | US | disclosed |
| WO-2024160271-A1 | SALT AND CRYSTAL FORM OF CYCLOALKENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏豪森药业集团有限公司 | 2024-08-08 | — | — | WO | disclosed |
| CN-118420603-A | Tromethamine salt crystal form of cycloolefin compound and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-118434730-A | Pharmaceutically acceptable salt and crystal form of GLP-1 receptor agonist and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-118401518-A | Crystalline form of GLP-1 receptor agonist and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240246958-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2024-07-25 | — | — | US | disclosed |
| WO-2024153244-A1 | NITROGEN-CONTAINING COMPOUND | 南京再明医药有限公司 | 2024-07-25 | — | — | WO | disclosed |
| CN-118359638-A | Compound serving as RET kinase inhibitor and preparation method and application thereof | 苏州朗睿生物医药有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-115611856-B | Piperidine derivative and pharmaceutical composition, preparation method and application thereof | 宜昌人福药业有限责任公司 | 2024-07-05 | — | — | CN | disclosed |
| US-12024507-B2 | Compounds as GLP-1R agonists | TERNS PHARMACEUTICALS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| CN-118239836-A | Safe and environment-friendly o-p-fluorobenzoyl chloride synthesis process and system | 江苏万隆化学有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-12018004-B2 | Carbamate compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2024-06-25 | — | — | US | disclosed |
| US-20240197673-A1 | COMPOSITION FOR PREVENTING OR TREATING NERVOUS SYSTEM DISEASES COMPRISING COMPOUND THAT INHIBITS MTOR SIGNALING PATHWAY AS ACTIVE INGREDIENT | ALIAD BIOPHARMA (KR) | 2024-06-20 | — | — | US | disclosed |
| EP-4384511-A1 | FUSED RING HETEROARYL COMPOUNDS AND USE THEREOF | Bisichem Co., Ltd. (KR) | 2024-06-19 | — | — | EP | disclosed |
| CN-113166134-B | Pyrrolidone derivatives as formyl peptide 2 receptor agonists | 百时美施贵宝公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-4382525-A1 | CYCLOALKENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| CN-115108992-B | Preparation method of 6-chloro-2-methyl-2H-indazol-5-amine | 浙江手心制药有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-115108992-B | Preparation method of 6-chloro-2-methyl-2H-indazol-5-amine | 浙江手心制药有限公司 | 2024-05-31 | — | — | CN | disclosed |
| WO-2024103010-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| EP-4364737-A2 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-117986264-A | Benzo nitrogen-containing polycyclic derivative regulator and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117881669-A | Condensed ring heteroaryl compounds and uses thereof | 比西切姆有限公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-4229056-B1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240109888-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-04 | — | — | US | disclosed |
| EP-4345096-A1 | PIPERIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Yichang Humanwell Pharmaceutical Co., Ltd. (CN) | 2024-04-03 | — | — | EP | disclosed |
| WO-2024064024-A1 | ((4-OXO-3,4-DIHYDROQUINAZOLIN-8-YL)METHYL)AMINE DERIVATIVES AS P13K INHIBITORS FOR THE TREATMENT OF CANCER | ONKURE, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| CN-113999180-B | Quinazoline compound, intermediate, preparation method, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-117751110-A | Cycloolefin derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-4339192-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | The Regents of the University of California (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11932639-B2 | Fused ring heteroaryl compounds as ALK4/5 inhibitors | BISICHEM CO., LTD. (KR) | 2024-03-19 | — | — | US | disclosed |
| CN-117642389-A | Piperidine derivative and pharmaceutical composition, preparation method and application thereof | 宜昌人福药业有限责任公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117580824-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-02-20 | — | — | CN | disclosed |
| US-11897851-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| WO-2024029819-A1 | PHARMACEUTICAL COMPOSITION CONTAINING BENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND METHOD FOR PREPARING SAME | 경희대학교 산학협력단 | 2024-02-08 | — | — | WO | disclosed |
| US-20240033318-A1 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | OHIO STATE INNOVATION FOUNDATION | 2024-02-01 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| WO-2023239789-A1 | TRICYCLIC PHTHALAZINONE PARP INHIBITORS AND METHODS OF USE | VALO HEALTH, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-117177970-A | Polycyclic derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-11820746-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-21 | — | — | US | disclosed |
| US-11820746-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-21 | — | — | US | disclosed |
| US-11820746-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-21 | — | — | US | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| CN-117003642-A | Synthesis method of Ensitrelvir key intermediate | 上海璨谊生物科技有限公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-117003642-A | Synthesis method of Ensitrelvir key intermediate | 上海璨谊生物科技有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20230348384-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230348384-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230348384-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| CN-114716382-B | Continuous flow synthesis process of Ensifelvir intermediate of anti-new crown drug | 拓信达(启东)医药生物科技有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-114716382-B | Continuous flow synthesis process of Ensifelvir intermediate of anti-new crown drug | 拓信达(启东)医药生物科技有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116924992-A | Method for preparing 6-chloro-2-methyl-2H-indazol-5-amine | 北京白泽瑞成医药科技有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230322756-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322756-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| EP-3478284-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3887366-B1 | PYRROLIDINONE DERIVATIVES AS FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3887366-B1 | PYRROLIDINONE DERIVATIVES AS FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-27 | — | — | EP | disclosed |
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-09-26 | — | — | US | disclosed |
| CN-116802181-A | Triazolopyridine compounds as kinase inhibitors | 百时美施贵宝公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4237413-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-4229056-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116554106-A | Preparation method of 6-chloro-2-methyl-2H-indazole-5-amine | 扬州市普林斯医药科技有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-115197098-B | Cell necrosis inhibitor | 北京生命科学研究所 | 2023-08-08 | — | — | CN | disclosed |
| CN-116496270-A | 4-aminopiperidine derivative and preparation method and application thereof | 四川大学华西医院 | 2023-07-28 | — | — | CN | disclosed |
| WO-2023138684-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO , INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| EP-4209490-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-07-12 | — | — | EP | disclosed |
| EP-4209490-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-07-12 | — | — | EP | disclosed |
| CN-116178256-B | Medicinal compound taking STING as target point, and preparation method and application thereof | 烟台大学 | 2023-07-07 | — | — | CN | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| WO-2023116882-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR | 江苏恒瑞医药股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023116882-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR | 江苏恒瑞医药股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023116879-A1 | CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR | 江苏恒瑞医药股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023116879-A1 | CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR | 江苏恒瑞医药股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| CN-116323599-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116283712-A | (aza) indole-, benzothiophene-and benzofuran-3-sulfonamides | 优时比制药有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| EP-4192831-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-110678177-B | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2023-06-13 | — | — | CN | disclosed |
| CN-113200970-B | Osthole isoxazoline derivatives, and preparation method and application thereof | 郑州大学 | 2023-06-13 | — | — | CN | disclosed |
| CN-116178256-A | Medicinal compound taking STING as target point, and preparation method and application thereof | 烟台大学 | 2023-05-30 | — | — | CN | disclosed |
| US-20230159512-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230150942-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-18 | — | — | US | disclosed |
| EP-3600312-B1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2023-05-17 | — | — | EP | disclosed |
| CN-109996790-B | Piperazine carbamates and methods of making and using the same | H.隆德贝克有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-110520127-B | Piperidinyl-substituted and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 | 武田药品工业株式会社 | 2023-05-16 | — | — | CN | disclosed |
| WO-2023076237-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| CN-116036078-A | (aza) indole-, benzothiophene-and benzofuran-3-sulfonamides | 优时比制药有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| CN-111032034-B | Spiro compounds and methods of making and using the same | H.隆德贝克有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-116003324-A | Synthesis method of 6-chloro-2-methyl-2H-indazole-5-amine | 杭州澳赛诺生物科技有限公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-116003324-A | Synthesis method of 6-chloro-2-methyl-2H-indazole-5-amine | 杭州澳赛诺生物科技有限公司 | 2023-04-25 | — | — | CN | disclosed |
| EP-4161902-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| CN-115884969-A | Condensed imidazole derivative, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20230099344-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | ARVINAS OPERATIONS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20230089180-A1 | FUSED RING HETEROARYL COMPOUNDS AND USE THEREOF | BISICHEM CO., LTD. (KR) | 2023-03-23 | — | — | US | disclosed |
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2023-03-23 | — | — | US | disclosed |
| CN-110845486-B | Triazole alcohol derivative and preparation method and application thereof | 中国人民解放军第二军医大学 | 2023-03-21 | — | — | CN | disclosed |
| US-20230078513-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2023-03-16 | — | — | US | disclosed |
| EP-4143183-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-115720578-A | Tricyclic derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-02-28 | — | — | CN | disclosed |
| WO-2023018313-A1 | FUSED RING HETEROARYL COMPOUNDS AND USE THEREOF | BISICHEM CO., LTD. (KR) | 2023-02-16 | — | — | WO | disclosed |
| US-11576946-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | OHIO STATE INNOVATION FOUNDATION (US) | 2023-02-14 | — | — | US | disclosed |
| WO-2023011539-A1 | CYCLOALKENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| WO-2023011539-A1 | CYCLOALKENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| CN-115667250-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-01-31 | — | — | CN | disclosed |
| US-11560356-B2 | Compounds and compositions for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-24 | — | — | US | disclosed |
| WO-2023284834-A1 | PIPERIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | 宜昌人福药业有限责任公司 | 2023-01-19 | — | — | WO | disclosed |
| CN-115611856-A | Piperidine derivative and pharmaceutical composition, preparation method and application thereof | 宜昌人福药业有限责任公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-115557895-A | Pyrazole derivative and preparation method and application thereof | 贵州大学 | 2023-01-03 | — | — | CN | disclosed |
| WO-2022266258-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | ARVINAS OPERATIONS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266258-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | ARVINAS OPERATIONS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| CN-110121499-B | (aza) indole-, benzothiophene-and benzofuran-3-sulfonamides | 优时比制药有限公司 | 2022-12-20 | — | — | CN | disclosed |
| US-11530189-B2 | Carbamate compounds and methods of making and using same | H. LUNDBECKA/S (DK) | 2022-12-20 | — | — | US | disclosed |
| US-11530189-B2 | Carbamate compounds and methods of making and using same | H. LUNDBECKA/S (DK) | 2022-12-20 | — | — | US | disclosed |
| EP-4100064-A1 | TARGETED PLASMA PROTEIN DEGRADATION | Novartis AG (CH) | 2022-12-14 | — | — | EP | disclosed |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
| CN-115335081-A | Targeted plasma protein degradation | 诺华股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-115197098-A | Cell necrosis inhibitor | 北京生命科学研究所 | 2022-10-18 | — | — | CN | disclosed |
| CN-113133969-B | Glucose-responsive insulin multivesicular liposome and preparation method and application thereof | 中国药科大学 | 2022-10-14 | — | — | CN | disclosed |
| CN-115108992-A | Preparation method of 6-chloro-2-methyl-2H-indazole-5-amine | 浙江手心制药有限公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-115108992-A | Preparation method of 6-chloro-2-methyl-2H-indazole-5-amine | 浙江手心制药有限公司 | 2022-09-27 | — | — | CN | disclosed |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| US-11426397-B2 | Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-08-30 | — | — | US | disclosed |
| WO-2022177280-A1 | COMPOSITION FOR PREVENTING OR TREATING NERVOUS SYSTEM DISEASES COMPRISING COMPOUND THAT INHIBITS MTOR SIGNALING PATHWAY AS ACTIVE INGREDIENT | 알리아드바이오파마 주식회사 | 2022-08-25 | — | — | WO | disclosed |
| CN-107108467-B | Cell necrosis inhibitor | 北京生命科学研究所 | 2022-08-19 | — | — | CN | disclosed |
| CN-114907335-A | 2- (benzothiophene-2-yl) benzo [ d ] oxazole derivative, preparation method and application | 陕西维世诺新材料有限公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-114716382-A | Continuous flow synthesis process of anti-neocoronal drug Ensittrelvir intermediate | 拓信达(启东)医药生物科技有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114716382-A | Continuous flow synthesis process of anti-neocoronal drug Ensittrelvir intermediate | 拓信达(启东)医药生物科技有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220204473-A1 | COMPOUND AS IRAK INHIBITOR | WUHAN CREATERNA SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2022-06-30 | — | — | US | disclosed |
| CN-109661229-B | Compounds and compositions for the treatment of cancer | 加利福尼亚大学董事会 | 2022-06-28 | — | — | CN | disclosed |
| CN-114671747-A | Synthesis method of 4-chloro-2-fluorobenzaldehyde | 浙江永太科技股份有限公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-114671747-A | Synthesis method of 4-chloro-2-fluorobenzaldehyde | 浙江永太科技股份有限公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-114671747-A | Synthesis method of 4-chloro-2-fluorobenzaldehyde | 浙江永太科技股份有限公司 | 2022-06-28 | — | — | CN | disclosed |
| US-20220185815-A1 | PYRROLOPYRAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-16 | — | — | US | disclosed |
| US-20220185815-A1 | PYRROLOPYRAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-16 | — | — | US | disclosed |
| CN-114605328-A | Preparation method of 6-chloro-2-methyl-2H-indazole-5-amine | 汉瑞药业(荆门)有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-114605328-A | Preparation method of 6-chloro-2-methyl-2H-indazole-5-amine | 汉瑞药业(荆门)有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-07 | — | — | US | disclosed |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-07 | — | — | US | disclosed |
| US-11345662-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2022-05-31 | — | — | US | disclosed |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| WO-2022094244-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20220127227-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| US-20220127227-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| WO-2022086828-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220119388-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2022-04-21 | — | — | US | disclosed |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | CYTOKINETICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| CN-110267963-B | MAGL inhibitors | H.隆德贝克有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-110248947-B | MAGL inhibitors | H.隆德贝克有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3675848-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2022-03-23 | — | — | EP | disclosed |
| CN-114181150-A | Pyrazole amide derivative, preparation method and application thereof | 沈阳万菱生物技术有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-109496213-B | Spiro compounds and methods of making and using the same | H.隆德贝克有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-108137513-B | Pyrimidine derivatives | ASKA 制药株式会社 | 2022-03-01 | — | — | CN | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20220048858-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| WO-2022028572-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| CN-113999180-A | Quinazoline compound, intermediate thereof, preparation method, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2022-02-01 | — | — | CN | disclosed |
| EP-3541822-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2022-01-19 | — | — | EP | disclosed |
| EP-3541822-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2022-01-19 | — | — | EP | disclosed |
| WO-2022007979-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2022-01-13 | — | — | WO | disclosed |
| WO-2022007866-A1 | FUSED TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | 深圳信立泰药业股份有限公司 | 2022-01-13 | — | — | WO | disclosed |
| EP-3936192-A1 | PYRROLOPYRAZOLE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2022-01-12 | — | — | EP | disclosed |
| US-20220002281-A1 | PYRROLIDINONE DERIVATIVES AS FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-01-06 | — | — | US | disclosed |
| US-20220002281-A1 | PYRROLIDINONE DERIVATIVES AS FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-01-06 | — | — | US | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-3914594-A1 | A FUSED RING HETEROARYL COMPOUND AS AN ALK4/5 INHIBITOR | Bisichem Co., Ltd. (KR) | 2021-12-01 | — | — | EP | disclosed |
| EP-3912977-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| CN-107660199-B | Piperazine carbamates and methods of making and using the same | H.隆德贝克有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-108738320-B | cGMP modulators for the treatment of cardiovascular diseases | 默沙东公司 | 2021-11-19 | — | — | CN | disclosed |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2021219019-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021219019-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-11161856-B2 | Spirocycle compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2021-11-02 | — | — | US | disclosed |
| US-11161856-B2 | Spirocycle compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2021-11-02 | — | — | US | disclosed |
| CN-113543852-A | Pyrrolopyrazole derivatives | 第一三共株式会社 | 2021-10-22 | — | — | CN | disclosed |
| EP-3372589-B1 | PYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2021-10-20 | — | — | EP | disclosed |
| US-11149037-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| US-11149037-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| CN-109153665-B | Novel 2-substituted indazoles, method for the production thereof, pharmaceutical preparations containing the same and use thereof for producing medicaments | 拜耳医药股份有限公司 | 2021-10-15 | — | — | CN | disclosed |
| EP-3887363-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| EP-3887365-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| EP-3887366-A1 | PYRROLIDINONE DERIVATIVES AS FORMYL PEPTIDE 2 RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-108601769-B | Pyrazole compounds and methods of making and using the same | H.隆德贝克有限公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-113330012-A | Fused heteroaryl compounds as ALK4/5 inhibitors | 比西切姆有限公司 | 2021-08-31 | — | — | CN | disclosed |
| CN-106316965-B | Quinazoline compound, intermediate thereof, preparation method, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2021-08-27 | — | — | CN | disclosed |
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2021-08-19 | — | — | US | disclosed |
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2021-08-19 | — | — | US | disclosed |
| EP-3515897-B1 | PIPERAZINE CARBAMATES AS MODULATORS OF MAGL AND/OR ABHD6 AND THEIR USE | H LUNDBECK AS (DK) | 2021-08-18 | — | — | EP | disclosed |
| EP-3515897-B1 | PIPERAZINE CARBAMATES AS MODULATORS OF MAGL AND/OR ABHD6 AND THEIR USE | H LUNDBECK AS (DK) | 2021-08-18 | — | — | EP | disclosed |
| WO-2021156792-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021156792-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2021-08-12 | — | — | WO | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3046920-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2021-08-04 | — | — | EP | disclosed |
| CN-113200970-A | Osthole isoxazoline derivatives, and preparation method and application thereof | 郑州大学 | 2021-08-03 | — | — | CN | disclosed |
| CN-107982266-B | Carbamate compounds and methods of making and using the same | H.隆德贝克有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-113166134-A | Pyrrolidone derivatives as formyl peptide 2 receptor agonists | 百时美施贵宝公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113166114-A | Cyclic tetramer compounds as proprotein convertase subtilisin/KEXIN 9 type (PCSK9) inhibitors for the treatment of metabolic disorders | 诺华股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113166101-A | Cyclic pentameric compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | 诺华股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3409671-B1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-21 | — | — | EP | disclosed |
| CN-113133969-A | Glucose-responsive insulin multivesicular liposome and preparation method and application thereof | 中国药科大学 | 2021-07-20 | — | — | CN | disclosed |
| US-20210214375-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2021-07-15 | — | — | US | disclosed |
| US-20210214375-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2021-07-15 | — | — | US | disclosed |
| US-20210188793-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | LUNDBECK LA JOLLA RESEARCH CENTER, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188793-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | LUNDBECK LA JOLLA RESEARCH CENTER, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2021127459-A1 | GPR139 RECEPTOR MODULATORS | BLACKTHORN THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20210169966-A1 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | OHIO STATE INNOVATION FOUNDATION | 2021-06-10 | — | — | US | disclosed |
| US-11026993-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2021-06-08 | — | — | US | disclosed |
| US-11026993-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2021-06-08 | — | — | US | disclosed |
| US-11021453-B2 | Carbamate compounds and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11021453-B2 | Carbamate compounds and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| CN-105593224-B | Novel quinazolinones as bromodomain inhibitors | 恒元生物医药科技(苏州)有限公司 | 2021-05-25 | — | — | CN | disclosed |
| EP-3271352-B1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2021-05-12 | — | — | EP | disclosed |
| EP-3271352-B1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2021-05-12 | — | — | EP | disclosed |
| WO-2021057890-A1 | 2H-BENZOPYRAN DERIVATIVES AS CRAC INHIBITORS | 南京明德新药研发有限公司 | 2021-04-01 | — | — | WO | disclosed |
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARM INC (US) | 2021-02-23 | — | — | US | disclosed |
| US-10899746-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-10899737-B2 | Piperazine carbamates and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| WO-2021009068-A1 | N-SUBSTITUTED-3,4-(FUSED 5-RING)-5-PHENYL-PYRROLIDINE-2-ONE COMPOUNDS AS INHIBITORS OF ISOQC AND/OR QC ENZYME | SCENIC IMMUNOLOGY B.V. (NL) | 2021-01-21 | — | — | WO | disclosed |
| EP-3765459-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Shire Human Genetic Therapies, Inc. (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20210009523-A1 | Compounds and Compositions for the Treatment of Cancer | RASCAL THERAPEUTICS, INC. | 2021-01-14 | — | — | US | disclosed |
| EP-3455226-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3455226-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2020-12-30 | — | — | EP | disclosed |
| CN-112135825-A | Plasma kallikrein inhibitors and uses thereof | 夏尔人类遗传性治疗公司 | 2020-12-25 | — | — | CN | disclosed |
| EP-3251679-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-12-16 | — | — | EP | disclosed |
| EP-3749365-A2 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | Ohio State Innovation Foundation (US) | 2020-12-16 | — | — | EP | disclosed |
| US-20200375969-A1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA CALIFORNIA, INC. | 2020-12-03 | — | — | US | disclosed |
| US-RE48335-E1 | Polymyxin derivatives as antimicrobial compounds | MONASH UNIVERSITY (AU) | 2020-12-01 | — | — | US | disclosed |
| EP-3544978-B1 | 2-[3-(ALKYLSULFONYL)-2H-INDAZOL-2-YL]-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2020-11-04 | — | — | EP | disclosed |
| CN-109651375-B | Tetrahydroquinazoline derivative and synthesis method and application thereof | 上海应用技术大学 | 2020-10-09 | — | — | CN | disclosed |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-2896397-B2 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-10-07 | — | — | EP | disclosed |
| EP-3177285-B1 | [5,6]-FUSED BICYCLIC ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-09-23 | — | — | EP | disclosed |
| US-10781211-B2 | Spirocycle compounds and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-10781211-B2 | Spirocycle compounds and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| EP-3423446-B1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | Bayer Pharma AG (DE) | 2020-09-16 | — | — | EP | disclosed |
| EP-3313837-B1 | CARBOLINE ANTIPARASITICS | ZOETIS SERVICES LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10765116-B2 | 2-[3-(alkylsulfonyl)-2H-indazol-2-yl]-3H-imidazo[4,5-B]pyridine derivatives and similar compounds as pesticides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2020-09-08 | — | — | US | disclosed |
| US-20200270223-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2020-08-27 | — | — | US | disclosed |
| US-20200270223-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2020-08-27 | — | — | US | disclosed |
| EP-3698782-A1 | CARBAMATE COMPOUNDS FOR USE IN THERAPY | Lundbeck La Jolla Research Center, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3698782-A1 | CARBAMATE COMPOUNDS FOR USE IN THERAPY | Lundbeck La Jolla Research Center, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10751335-B2 | Signaling-biased mu opioid receptor agonists | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-08-25 | — | — | US | disclosed |
| EP-3377060-B1 | PYRAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-1651658-B2 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-08-12 | — | — | EP | disclosed |
| US-10730874-B2 | Inhibitors of plasma kallikrein and uses thereof | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10730874-B2 | Inhibitors of plasma kallikrein and uses thereof | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| CN-106414480-B | Polymyxin derivatives as antimicrobial compounds | 莫纳什大学 | 2020-08-04 | — | — | CN | disclosed |
| WO-2020153676-A1 | A FUSED RING HETEROARYL COMPOUND AS AN ALK4/5 INHIBITOR | BISICHEM CO., LTD. (KR) | 2020-07-30 | — | — | WO | disclosed |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | AMGEN INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200231591-A1 | FUSED RING HETEROARYL COMPOUNDS AS ALK4/5 INHIBITORS | BISICHEM CO., LTD. (KR) | 2020-07-23 | — | — | US | disclosed |
| US-20200223829-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2020-07-16 | — | — | US | disclosed |
| US-20200223830-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | CYTOKINETICS, INC. | 2020-07-16 | — | — | US | disclosed |
| EP-3680237-A1 | PROCESS FOR PREPARING SUBSTITUTED 2,3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | Arrien Pharmaceuticals LLC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10710967-B2 | Pyrimidine derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2020-07-14 | — | — | US | disclosed |
| EP-3675848-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Lundbeck La Jolla Research Center, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10682319-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-06-16 | — | — | US | disclosed |
| WO-2020112583-A1 | PYRROLIDINONE DERIVATIVES AS FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020112583-A1 | PYRROLIDINONE DERIVATIVES AS FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020110009-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020110008-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2020-06-04 | — | — | WO | disclosed |
| US-20200164024-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200164024-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-05-28 | — | — | US | disclosed |
| EP-3645516-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | Janssen Pharmaceutica NV (BE) | 2020-05-06 | — | — | EP | disclosed |
| CN-111032034-A | Spiro compounds and methods of making and using the same | 隆德贝克拉荷亚研究中心有限公司 | 2020-04-17 | — | — | CN | disclosed |
| EP-3634404-A1 | PYRAZOLE MAGL INHIBITORS | Lundbeck La Jolla Research Center, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-10618893-B2 | GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICALS NV (BE) | 2020-04-14 | — | — | US | disclosed |
| EP-3044223-B1 | 2,3-DIHYDRO-1H-INDEN-1-ONE DERIVATIVES AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA) ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | ARRIEN PHARMACEUTICALS LLC (US) | 2020-04-01 | — | — | EP | disclosed |
| EP-3394067-B1 | 4-AMINO-2-(1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL)-6-OXO-6,7-DIHYDRO-5H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THE RESPECTIVE (1H-INDAZOL-3-YL) DERIVATIVES AS CGMP MODULATORS FOR TREATING CARDIOVASCULAR DISEASES | MERCK SHARP & DOHME (US) | 2020-04-01 | — | — | EP | disclosed |
| EP-2800565-B1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-2800565-B1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2020-03-25 | — | — | EP | disclosed |
| CN-106986809-B | Synthesis method of 5-bromo-6-chloro-3-indoxyl | 广东省微生物研究所（广东省微生物分析检测中心） | 2020-03-24 | — | — | CN | disclosed |
| US-20200087304-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-03-19 | — | — | US | disclosed |
| US-20200087304-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-03-19 | — | — | US | disclosed |
| EP-3623371-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS | Axovant Sciences GmbH (CH) | 2020-03-18 | — | — | EP | disclosed |
| US-20200071280-A1 | PYRIMIDINE DERIVATIVE | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-05 | — | — | US | disclosed |
| CN-110845486-A | Triazole alcohol derivative and preparation method and application thereof | 中国人民解放军第二军医大学 | 2020-02-28 | — | — | CN | disclosed |
| US-10570129-B2 | Carboline antiparasitics | ZOETIS SERVICES LLC (US) | 2020-02-25 | — | — | US | disclosed |
| CN-110809574-A | Heteroaryl dihydropyrimidine derivatives and methods for treating hepatitis b infection | 詹森药业有限公司 | 2020-02-18 | — | — | CN | disclosed |
| EP-3600312-A1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | Takeda Pharmaceutical Company Limited (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-20200031822-A1 | CARBOLINE ANTIPARASITICS | ZOETIS SERVICES LLC (US) | 2020-01-30 | — | — | US | disclosed |
| CN-110683981-A | Synthesis method of 5-bromo-4-chloro-1-acetyl-3-indophenol | 湖南恒泰生物医药有限公司 | 2020-01-14 | — | — | CN | disclosed |
| CN-110678177-A | Pyrazole MAGL inhibitors | 隆德贝克拉荷亚研究中心有限公司 | 2020-01-10 | — | — | CN | disclosed |
| CN-106414434-B | Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes | 詹森药业有限公司 | 2019-12-31 | — | — | CN | disclosed |
| US-20190345104-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2019-11-14 | — | — | US | disclosed |
| EP-3562820-A1 | (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES | UCB Pharma GmbH (DE) | 2019-11-06 | — | — | EP | disclosed |
| US-10463753-B2 | Radiolabeled monoacylglycerol lipase occupancy probe | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10463753-B2 | Radiolabeled monoacylglycerol lipase occupancy probe | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-2892893-B2 | 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-10-16 | — | — | EP | disclosed |
| US-10435396-B2 | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs | BAYER PHARMA AKTIEGESELLSCHAFT (DE) | 2019-10-08 | — | — | US | disclosed |
| EP-3233087-B1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS | AXOVANT SCIENCES GMBH (DE) | 2019-10-02 | — | — | EP | disclosed |
| EP-3233087-B1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS | AXOVANT SCIENCES GMBH (DE) | 2019-10-02 | — | — | EP | disclosed |
| EP-3544978-A1 | 2-[3-(ALKYLSULFONYL)-2H-INDAZOL-2-YL]-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AND SIMILAR COMPOUNDS AS PESTICIDES | Bayer CropScience Aktiengesellschaft (DE) | 2019-10-02 | — | — | EP | disclosed |
| US-10428076-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428062-B2 | Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors | AXOVANT SCIENCES GMBH (CH) | 2019-10-01 | — | — | US | disclosed |
| US-10428062-B2 | Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors | AXOVANT SCIENCES GMBH (CH) | 2019-10-01 | — | — | US | disclosed |
| EP-3541822-A1 | MAGL INHIBITORS | Abide Therapeutics, Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190284182-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
| WO-2019178129-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20190284182-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
| US-20190274306-A1 | 2-[3-(ALKYLSULFONYL)-2H-INDAZOL-2-YL]-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AND SIMILAR COMPOUNDS AS PESTICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-09-12 | — | — | US | disclosed |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190263775-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190256494-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2019-08-22 | — | — | US | disclosed |
| US-10370370-B2 | Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors | AXOVANT SCIENCES GMBH (CH) | 2019-08-06 | — | — | US | disclosed |
| US-10370370-B2 | Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors | AXOVANT SCIENCES GMBH (CH) | 2019-08-06 | — | — | US | disclosed |
| WO-2019148194-A2 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | OHIO STATE INNOVATION FOUNDATION (US) | 2019-08-01 | — | — | WO | disclosed |
| EP-3515897-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-20190202801-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2019-07-04 | — | — | US | disclosed |
| US-20190202801-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2019-07-04 | — | — | US | disclosed |
| US-10316028-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-06-11 | — | — | US | disclosed |
| EP-3478284-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | The Regents of The University of California (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-3455226-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2019-03-14 | — | — | US | disclosed |
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20190071432-A1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-07 | — | — | US | disclosed |
| WO-2019046330-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019046330-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-20190071435-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-07 | — | — | US | disclosed |
| US-20190055214-A1 | SIGNALING-BIASED MU OPIOID RECEPTOR AGONISTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-02-21 | — | — | US | disclosed |
| EP-3027604-B1 | NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD (CA) | 2019-02-20 | — | — | EP | disclosed |
| US-20190046668-A1 | RADIOLABELED MONOACYLGLYCEROL LIPASE OCCUPANCY PROBE | H. LUNDBECK A/S (DK) | 2019-02-14 | — | — | US | disclosed |
| US-20190046668-A1 | RADIOLABELED MONOACYLGLYCEROL LIPASE OCCUPANCY PROBE | H. LUNDBECK A/S (DK) | 2019-02-14 | — | — | US | disclosed |
| US-10189839-B2 | Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase | ACTELION PHARMACEUTICALS LTD (CH) | 2019-01-29 | — | — | US | disclosed |
| EP-3430007-A1 | SIGNALING-BIASED MU OPIOID RECEPTOR AGONISTS | The Scripps Research Institute (US) | 2019-01-23 | — | — | EP | disclosed |
| US-10183938-B2 | Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors | AXOVANT SCIENCES GMBH (CH) | 2019-01-22 | — | — | US | disclosed |
| US-10183938-B2 | Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors | AXOVANT SCIENCES GMBH (CH) | 2019-01-22 | — | — | US | disclosed |
| EP-3423446-A1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | Bayer Pharma Aktiengesellschaft (DE) | 2019-01-09 | — | — | EP | disclosed |
| US-10172866-B2 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | ARRIEN PHARMACEUTICALS LLC (US) | 2019-01-08 | — | — | US | disclosed |
| WO-2019001420-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-03 | — | — | WO | disclosed |
| US-20180370961-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-12-27 | — | — | US | disclosed |
| EP-3409671-A1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica NV (BE) | 2018-12-05 | — | — | EP | disclosed |
| WO-2018217809-A1 | PYRAZOLE MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-11-29 | — | — | WO | disclosed |
| EP-3398944-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| US-10118922-B2 | GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | disclosed |
| EP-3394067-A1 | 4-AMINO-2-(1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL)-6-OXO-6,7-DIHYDRO-5H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THE RESPECTIVE (1H-INDAZOL-3-YL) DERIVATIVES AS CGMP MODULATORS FOR TREATING CARDIOVASCULAR DISEASES | Merck Sharp & Dohme Corp. (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20180305366-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME CORP. (US) | 2018-10-25 | — | — | US | disclosed |
| CN-108689990-A | A kind of preparation method of biaryl quinolin compound | 湖南华腾制药有限公司 | 2018-10-23 | — | — | CN | disclosed |
| WO-2018191146-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
| US-10100042-B2 | [5,6]—fused bicyclic antidiabetic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-10-16 | — | — | US | disclosed |
| US-10093635-B2 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-10093630-B2 | Pyrazole compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180282612-A1 | Method and Compositions for Hydraulic Fracturing and for Tracing Formation Water | NCS Multistage, LLC | 2018-10-04 | — | — | US | disclosed |
| US-20180282363-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-10-04 | — | — | US | disclosed |
| WO-2018183145-A1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | WO | disclosed |
| EP-3144303-B1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2018-09-26 | — | — | EP | disclosed |
| EP-3377060-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2018-09-26 | — | — | EP | disclosed |
| US-20180263934-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-09-20 | — | — | US | disclosed |
| EP-3372589-A1 | PYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2018-09-12 | — | — | EP | disclosed |
| EP-2721023-B1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS NC INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20180208568-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2018-07-26 | — | — | US | disclosed |
| US-20180208568-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2018-07-26 | — | — | US | disclosed |
| US-20180208568-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2018-07-26 | — | — | US | disclosed |
| US-10030020-B2 | Spirocycle compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030020-B2 | Spirocycle compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030020-B2 | Spirocycle compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030027-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180201609-A1 | INDAZOLE AND AZAINDAZOLE COMPOUNDS AS IRAK-4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-07-19 | — | — | US | disclosed |
| US-10017684-B2 | Method and compositions for hydraulic fracturing and for tracing formation water | SPECTRUM TRACER SERVICES, LLC (US) | 2018-07-10 | — | — | US | disclosed |
| WO-2018122232-A1 | (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES | UCB PHARMA GMBH (DE) | 2018-07-05 | — | — | WO | disclosed |
| WO-2018122232-A1 | (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES | UCB PHARMA GMBH (DE) | 2018-07-05 | — | — | WO | disclosed |
| EP-3334740-A1 | GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF 7-NICOTINIC ACETYLCHOLINE RECEPTORS | Axovant Sciences GmbH (DE) | 2018-06-20 | — | — | EP | disclosed |
| EP-3067350-B1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS NC INC (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9994537-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994537-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994537-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20180155344-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-06-07 | — | — | US | disclosed |
| WO-2018095953-A1 | 2-[3-(ALKYLSULFONYL)-2H-INDAZOL-2-YL]-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AND SIMILAR COMPOUNDS AS PESTICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | WO | disclosed |
| EP-3326627-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3326627-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9981930-B1 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981930-B1 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981930-B1 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981960-B2 | Pyrrolidine compound and application as melanocortin receptor agonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-29 | — | — | US | disclosed |
| WO-2018093947-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093946-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093946-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| EP-3322698-A1 | INDAZOLE AND AZAINDAZOLE COMPOUNDS AS IRAK-4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2018-05-23 | — | — | EP | disclosed |
| US-9974762-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-05-22 | — | — | US | disclosed |
| US-20180134675-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
| US-20180134675-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
| US-20180134675-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
| US-20180134696-A1 | Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134696-A1 | Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
| EP-3313837-A1 | CARBOLINE ANTIPARASITICS | Zoetis Services LLC (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9957242-B2 | Carbamate compounds and methods of making and using same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957242-B2 | Carbamate compounds and methods of making and using same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957242-B2 | Carbamate compounds and methods of making and using same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-01 | — | — | US | disclosed |
| EP-3114123-B1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-25 | — | — | EP | disclosed |
| EP-3307269-A1 | AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF A7-NICOTINIC ACETYLCHOLINE RECEPTORS | Axovant Sciences GmbH (DE) | 2018-04-18 | — | — | EP | disclosed |
| US-20180092924-A1 | NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2018-04-05 | — | — | US | disclosed |
| US-9932309-B2 | 2-oxo-3,4-dihydropyridine-5-carboxylates and their use | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2018-04-03 | — | — | US | disclosed |
| WO-2018053447-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018053447-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| EP-3292127-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | Actelion Pharmaceuticals Ltd (CH) | 2018-03-14 | — | — | EP | disclosed |
| CN-107660199-A | Piperazine carbamate and its preparation and application | 阿比德治疗公司 | 2018-02-02 | — | — | CN | disclosed |
| EP-3271352-A2 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2018-01-24 | — | — | EP | disclosed |
| EP-3071578-B1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-01-10 | — | — | EP | disclosed |
| WO-2018005678-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-01-04 | — | — | WO | disclosed |
| US-9855271-B2 | Quinazolinones as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2018-01-02 | — | — | US | disclosed |
| US-9856248-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170369486-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS | AXOVANT SCIENCES GMBH (CH) | 2017-12-28 | — | — | US | disclosed |
| US-20170369486-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS | AXOVANT SCIENCES GMBH (CH) | 2017-12-28 | — | — | US | disclosed |
| US-9850237-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| EP-3251679-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-12-06 | — | — | EP | disclosed |
| US-9828379-B2 | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof | ABIDE THERAPEUTICS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828379-B2 | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof | ABIDE THERAPEUTICS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828379-B2 | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof | ABIDE THERAPEUTICS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170334874-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-23 | — | — | US | disclosed |
| US-20170334874-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-23 | — | — | US | disclosed |
| US-20170334874-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-23 | — | — | US | disclosed |
| EP-3083597-B1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES AS CAV2.2 CALCIUM CHANNEL BLOCKERS | GRUENENTHAL GMBH (DE) | 2017-11-22 | — | — | EP | disclosed |
| EP-3083597-B1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES AS CAV2.2 CALCIUM CHANNEL BLOCKERS | GRUENENTHAL GMBH (DE) | 2017-11-22 | — | — | EP | disclosed |
| WO-2017197192-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017197192-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20170327500-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| US-20170327500-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| US-20170327500-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| EP-2865671-B1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-9802921-B2 | Fluoromethyl-substituted pyrrole carboxamides iv | GRUENENTHAL GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9802921-B2 | Fluoromethyl-substituted pyrrole carboxamides iv | GRUENENTHAL GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9802921-B2 | Fluoromethyl-substituted pyrrole carboxamides iv | GRUENENTHAL GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-20170306217-A1 | METHOD AND COMPOSITIONS FOR HYDRAULIC FRACTURING AND FOR TRACING FORMATION WATER | NCS Multistage, LLC | 2017-10-26 | — | — | US | disclosed |
| EP-3233087-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS | Axovant Sciences GmbH (DE) | 2017-10-25 | — | — | EP | disclosed |
| US-20170290790-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-12 | — | — | US | disclosed |
| US-9771341-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771341-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771341-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| WO-2017161017-A1 | SIGNALING-BIASED MU OPIOID RECEPTOR AGONISTS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-09-21 | — | — | WO | disclosed |
| US-9765092-B2 | Tricyclic piperidine compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2017-09-19 | — | — | US | disclosed |
| EP-2896397-B1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-3071567-B1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | ACTELION PHARMACEUTICALS LTD (CH) | 2017-09-06 | — | — | EP | disclosed |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2017-08-31 | — | — | US | disclosed |
| WO-2017143283-A1 | RADIOLABELED MONOACYLGLYCEROL LIPASE OCCUPANCY PROBE | ABIDE THERAPEUTICS, INC. (US) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017143283-A1 | RADIOLABELED MONOACYLGLYCEROL LIPASE OCCUPANCY PROBE | ABIDE THERAPEUTICS, INC. (US) | 2017-08-24 | — | — | WO | disclosed |
| US-20170210727-A1 | [5,6]-FUSED BICYCLIC ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210710-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-07-27 | — | — | US | disclosed |
| EP-3004110-B1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-07-26 | — | — | EP | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| US-20170190697-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-07-06 | — | — | US | disclosed |
| WO-2017107052-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112617-A1 | 4-AMINO-2-(1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL)-6-OXO-6,7-DIHYDRO-5H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THE RESPECTIVE (1H-INDAZOL-3-YL) DERIVATIVES AS CGMP MODULATORS FOR TREATING CARDIOVASCULAR DISEASES | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174675-A9 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED | 2017-06-22 | — | — | US | disclosed |
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME LLC | 2017-06-22 | — | — | US | disclosed |
| EP-3177285-A1 | [5,6]-FUSED BICYCLIC ANTIDIABETIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-3174872-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | Université de Lille 2 Droit et Santé (FR) | 2017-06-07 | — | — | EP | disclosed |
| US-20170137469-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2017-05-18 | — | — | US | disclosed |
| US-20170121320-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-05-04 | — | — | US | disclosed |
| EP-2766344-B1 | EP1 RECEPTOR LIGANDS | ESTEVE LABOR DR (ES) | 2017-05-03 | — | — | EP | disclosed |
| EP-2870144-B1 | OREXIN RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2017-04-19 | — | — | EP | disclosed |
| EP-3144303-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | Array Biopharma, Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20170073320-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-03-16 | — | — | US | disclosed |
| US-20170073320-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-03-16 | — | — | US | disclosed |
| US-20170073320-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-03-16 | — | — | US | disclosed |
| CN-103130745-B | Diaryl piperazine compounds and its medical usage | 中国人民解放军军事医学科学院毒物药物研究所 | 2017-03-15 | — | — | CN | disclosed |
| WO-2017027600-A1 | GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| US-20170044155-A1 | Geminal Substituted Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | AXOVANT SCIENCES GMBH (CH) | 2017-02-16 | — | — | US | disclosed |
| US-20170044155-A1 | Geminal Substituted Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | AXOVANT SCIENCES GMBH (CH) | 2017-02-16 | — | — | US | disclosed |
| US-20170044155-A1 | Geminal Substituted Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | AXOVANT SCIENCES GMBH (CH) | 2017-02-16 | — | — | US | disclosed |
| US-9567302-B2 | Carbamate compounds and of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567302-B2 | Carbamate compounds and of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567302-B2 | Carbamate compounds and of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| EP-3126376-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | Monash University (AU) | 2017-02-08 | — | — | EP | disclosed |
| EP-2688870-B1 | HETEROCYCLIC AMINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-9556187-B2 | Substituted pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-01-31 | — | — | US | disclosed |
| US-9556139-B2 | 6-substituted phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9555044-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-01-31 | — | — | US | disclosed |
| WO-2017009798-A1 | INDAZOLE AND AZAINDAZOLE COMPOUNDS AS IRAK-4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-01-19 | — | — | WO | disclosed |
| WO-2017005137-A1 | QUINAZOLINE COMPOUND, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USES THEREOF | 吉林大学 | 2017-01-12 | — | — | WO | disclosed |
| EP-3114123-A1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica NV (BE) | 2017-01-11 | — | — | EP | disclosed |
| EP-3112370-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | Nissan Chemical Industries, Ltd. (JP) | 2017-01-04 | — | — | EP | disclosed |
| WO-2016209635-A1 | CARBOLINE ANTIPARASITICS | ZOETIS SERVICES LLC (US) | 2016-12-29 | — | — | WO | disclosed |
| EP-2892893-B1 | 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2016-12-21 | — | — | EP | disclosed |
| WO-2016201096-A1 | AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF A7-NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-9518015-B2 | EP1 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-12-13 | — | — | US | disclosed |
| EP-2906534-B1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES | GRUENENTHAL GMBH (DE) | 2016-12-07 | — | — | EP | disclosed |
| EP-2906534-B1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES | GRUENENTHAL GMBH (DE) | 2016-12-07 | — | — | EP | disclosed |
| WO-2016191366-A1 | MODULATORS FOR NICOTINIC ACETYLCHOLINE RECEPTOR α2 AND α4 SUBUNITS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-12-01 | — | — | WO | disclosed |
| WO-2016177690-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-11-10 | — | — | WO | disclosed |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-11-10 | — | — | US | disclosed |
| US-9487495-B2 | Carbamate compounds and of making and using same | THE SCRIPTS RESEARCH INSTITUTE (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487495-B2 | Carbamate compounds and of making and using same | THE SCRIPTS RESEARCH INSTITUTE (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487515-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487515-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2016-11-08 | — | — | US | disclosed |
| EP-3083613-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES IV | Grünenthal GmbH (DE) | 2016-10-26 | — | — | EP | disclosed |
| EP-3083597-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES III | Grünenthal GmbH (DE) | 2016-10-26 | — | — | EP | disclosed |
| US-20160297803-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES IV | GRUENENTHAL GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
| US-20160297803-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES IV | GRUENENTHAL GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
| US-20160297803-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES IV | GRUENENTHAL GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
| US-20160289232-A1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | ACTELION PHARMACEUTICALS LTD (CH) | 2016-10-06 | — | — | US | disclosed |
| US-20160289186-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES III | GRUENENTHAL GMBH (DE) | 2016-10-06 | — | — | US | disclosed |
| US-20160289186-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES III | GRUENENTHAL GMBH (DE) | 2016-10-06 | — | — | US | disclosed |
| EP-3071567-A1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | Actelion Pharmaceuticals Ltd (CH) | 2016-09-28 | — | — | EP | disclosed |
| EP-3071578-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | Actelion Pharmaceuticals Ltd (CH) | 2016-09-28 | — | — | EP | disclosed |
| WO-2016149401-A2 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20160272602-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2016-09-22 | — | — | US | disclosed |
| US-20160272602-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2016-09-22 | — | — | US | disclosed |
| WO-2016149401-A2 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20160272655-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-09-22 | — | — | US | disclosed |
| US-9447086-B2 | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-09-20 | — | — | US | disclosed |
| EP-3067350-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| CN-104080787-B | Pyrazolo pyrrolidine compound | 诺华股份有限公司 | 2016-09-14 | — | — | CN | disclosed |
| US-20160237078-A9 | NOVEL 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160237079-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMA (US) | 2016-08-18 | — | — | US | disclosed |
| CN-103732597-B | Tricyclic heterocyclic compounds and JAK inhibitors | 日产化学工业株式会社 | 2016-08-17 | — | — | CN | disclosed |
| CN-102731381-B | The polysubstituted aryl of 6-()-4-aminopyridine formic acid esters and the purposes as herbicide thereof | 美国陶氏益农公司 | 2016-08-17 | — | — | CN | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160213627-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | XENTHERA, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160213678-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2016-07-28 | — | — | US | disclosed |
| US-20160213676-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | XENTHERA, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160213676-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | XENTHERA, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160213627-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | XENTHERA, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160193218-A1 | NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. (CA) | 2016-07-07 | — | — | US | disclosed |
| WO-2016100184-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100184-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-9365574-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-3027604-A2 | NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS | Zenith Epigenetics Corp. (CA) | 2016-06-08 | — | — | EP | disclosed |
| US-9359315-B2 | Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | ARRIEN PHARMACEUTICALS LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359315-B2 | Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | ARRIEN PHARMACEUTICALS LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-9351962-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2826774-B1 | Intermediates for 6-substituted phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20160137649-A1 | PYRROLO-PYRROLE CARBAMATE AND RELATED ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ABIDE THERAPEUTICS, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160137649-A1 | PYRROLO-PYRROLE CARBAMATE AND RELATED ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ABIDE THERAPEUTICS, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160137649-A1 | PYRROLO-PYRROLE CARBAMATE AND RELATED ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ABIDE THERAPEUTICS, INC. | 2016-05-19 | — | — | US | disclosed |
| EP-3016653-A1 | PYRROLO-PYRROLE CARBAMATE AND RELATED ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | Abide Therapeutics, Inc. (US) | 2016-05-11 | — | — | EP | disclosed |
| WO-2016069949-A1 | COMPOSITIONS AND FORMULATIONS OF METHYLERTHRITOL PHOSPHATE PATHWAY INHIBITORS AND USES THEREOF | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| US-9328121-B1 | Fused heterocyclic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| CN-105517547-A | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof | ABIDE THERAPEUTICS | 2016-04-20 | — | — | CN | disclosed |
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-20160102100-A1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2016-04-14 | — | — | US | disclosed |
| EP-3004110-A1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2016-04-13 | — | — | EP | disclosed |
| US-20160095843-A1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-07 | — | — | US | disclosed |
| US-9302988-B2 | Fluoromethyl-substituted pyrrole carboxamides | Grünenthal GmbH (DE) | 2016-04-05 | — | — | US | disclosed |
| US-9302988-B2 | Fluoromethyl-substituted pyrrole carboxamides | Grünenthal GmbH (DE) | 2016-04-05 | — | — | US | disclosed |
| US-9302988-B2 | Fluoromethyl-substituted pyrrole carboxamides | Grünenthal GmbH (DE) | 2016-04-05 | — | — | US | disclosed |
| US-9260436-B2 | Fused heterocyclic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-02-16 | — | — | US | disclosed |
| WO-2016022446-A1 | [5,6]-FUSED BICYCLIC ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016016238-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2016-02-04 | — | — | WO | disclosed |
| US-9249160-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| EP-2970161-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | disclosed |
| EP-2575473-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2016007837-A1 | CARBONYL LINKED BICYCLIC HETEROARYL ANTIBIOTIC TOLERANCE INHIBITORS | SPERO THERAPEUTICS, INC. (US) | 2016-01-14 | — | — | WO | disclosed |
| WO-2016007837-A1 | CARBONYL LINKED BICYCLIC HETEROARYL ANTIBIOTIC TOLERANCE INHIBITORS | SPERO THERAPEUTICS, INC. (US) | 2016-01-14 | — | — | WO | disclosed |
| EP-2785717-B1 | PYRAZOLOPYRROLIDINE COMPOUNDS | NOVARTIS AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| CN-105209446-A | GPR120 agonists for the treatment of type ii diabetes | JANSSEN PHARMACEUTICA NV | 2015-12-30 | — | — | CN | disclosed |
| US-9220265-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9216999-B2 | Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
| WO-2015179559-A2 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| WO-2015179559-A2 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-9169250-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169250-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2015-10-27 | — | — | US | disclosed |
| WO-2015149131-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2015-10-08 | — | — | WO | disclosed |
| US-9150592-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9145354-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-9145354-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-9145354-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-20150265586-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | DAIICHI SANKYO, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150265586-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | DAIICHI SANKYO, INC. | 2015-09-24 | — | — | US | disclosed |
| US-9133148-B2 | Carbamate compounds and of making and using same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133148-B2 | Carbamate compounds and of making and using same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133148-B2 | Carbamate compounds and of making and using same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-09-15 | — | — | US | disclosed |
| WO-2015134039-A1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-11 | — | — | WO | disclosed |
| EP-2767536-B1 | Isoxazolo-pyridine derivatives | HOFFMANN LA ROCHE (CH) | 2015-09-02 | — | — | EP | disclosed |
| US-20150232442-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2015-08-20 | — | — | US | disclosed |
| EP-2906534-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES | Grünenthal GmbH (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-9096567-B2 | 6-substituted phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2015-08-04 | — | — | US | disclosed |
| EP-2896397-A1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-07-22 | — | — | EP | disclosed |
| EP-2892893-A1 | 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F.HOFFMANN-LA ROCHE AG (CH) | 2015-07-15 | — | — | EP | disclosed |
| US-20150191474-A1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-07-09 | — | — | US | disclosed |
| US-9073908-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-9067898-B1 | Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-30 | — | — | US | disclosed |
| WO-2015090599-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES IV | Grünenthal GmbH (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015090599-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES IV | Grünenthal GmbH (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015090603-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES III | Grünenthal GmbH (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015090603-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES III | Grünenthal GmbH (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015075025-A1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | ACTELION PHARMACEUTICALS LTD (CH) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015075023-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-05-28 | — | — | WO | disclosed |
| US-20150148330-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2015-05-28 | — | — | US | disclosed |
| US-20150148330-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2015-05-28 | — | — | US | disclosed |
| US-20150148330-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2015-05-28 | — | — | US | disclosed |
| EP-2870144-A1 | OREXIN RECEPTOR ANTAGONISTS | Heptares Therapeutics Limited (GB) | 2015-05-13 | — | — | EP | disclosed |
| US-20150126498-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-05-07 | — | — | US | disclosed |
| US-20150126566-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED | 2015-05-07 | — | — | US | disclosed |
| US-20150119402-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | UNIV CALIFORNIA (US) | 2015-04-30 | — | — | US | disclosed |
| EP-2865671-A1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2015-04-29 | — | — | EP | disclosed |
| EP-2149563-B9 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | KOWA CO (JP) | 2015-04-22 | — | — | EP | disclosed |
| WO-2015042397-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20150080364-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080364-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080364-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| EP-2847179-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | The Regents of The University of California (US) | 2015-03-18 | — | — | EP | disclosed |
| US-20150072980-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | XENTHERA, INC. | 2015-03-12 | — | — | US | disclosed |
| US-20150072980-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | XENTHERA, INC. | 2015-03-12 | — | — | US | disclosed |
| US-8975417-B2 | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| US-8969341-B2 | Pyrazolopyrrolidine compounds | NOVARTIS AG (CH) | 2015-03-03 | — | — | US | disclosed |
| US-8962856-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-02-24 | — | — | US | disclosed |
| US-20150051199-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-19 | — | — | US | disclosed |
| US-20150051199-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-19 | — | — | US | disclosed |
| US-20150051199-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-19 | — | — | US | disclosed |
| US-20150031687-A1 | Novel 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-01-29 | — | — | US | disclosed |
| EP-2828253-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2015-01-28 | — | — | EP | disclosed |
| EP-2826774-A1 | Intermediates for 6-substituted phenoxychroman carboxylic acid derivatives | Array Biopharma, Inc. (US) | 2015-01-21 | — | — | EP | disclosed |
| WO-2015003002-A1 | PYRROLO-PYRROLE CARBAMATE AND RELATED ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ABIDE THERAPEUTICS, INC. (US) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015003002-A1 | PYRROLO-PYRROLE CARBAMATE AND RELATED ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ABIDE THERAPEUTICS, INC. (US) | 2015-01-08 | — | — | WO | disclosed |
| EP-2149563-B1 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | KOWA CO (JP) | 2015-01-07 | — | — | EP | disclosed |
| CN-102933572-B | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | HOFFMANN LA ROCHE | 2015-01-07 | — | — | CN | disclosed |
| EP-2227467-B1 | ISOXAZOLO-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | disclosed |
| EP-2514756-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-12-17 | — | — | EP | disclosed |
| WO-2014191896-A1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-12-04 | — | — | WO | disclosed |
| US-20140350010-A1 | Pyrazolopyrrolidine Compounds | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| US-20140349990-A1 | Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| EP-2440526-B1 | 3-HALO-6-(ARLY)-4-IMINOTETRAHYDROPICOLINATES AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2014-11-12 | — | — | EP | disclosed |
| EP-2800565-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2014-11-12 | — | — | EP | disclosed |
| US-8877783-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877782-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140323475-A1 | EP1 RECEPTOR LIGANDS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2014-10-30 | — | — | US | disclosed |
| EP-2785717-A1 | PYRAZOLOPYRROLIDINE COMPOUNDS | Novartis AG (CH) | 2014-10-08 | — | — | EP | disclosed |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
| WO-2014159054-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-02 | — | — | WO | disclosed |
| US-8846719-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140288040-A1 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | ASTEX THERAPEUTICS LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| US-20140288107-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2014-09-25 | — | — | US | disclosed |
| US-20140275179-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| EP-2773613-A1 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | Astex Therapeutics Limited (GB) | 2014-09-10 | — | — | EP | disclosed |
| EP-2773615-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2014-09-10 | — | — | EP | disclosed |
| US-20140243365-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | DAIICHI SANKYO, INC. | 2014-08-28 | — | — | US | disclosed |
| US-20140243365-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | DAIICHI SANKYO, INC. | 2014-08-28 | — | — | US | disclosed |
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | disclosed |
| EP-2307397-B1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2014-08-20 | — | — | EP | disclosed |
| EP-2767536-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2014-08-20 | — | — | EP | disclosed |
| EP-2766344-A1 | EP1 RECEPTOR LIGANDS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2014-08-20 | — | — | EP | disclosed |
| US-8802673-B2 | Heterocyclic amine derivatives | Hoffmann-La Roche Inc (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140221342-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
| EP-2114906-B1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8796001-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8785403-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | US | disclosed |
| EP-2742049-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | Nissan Chemical Industries, Ltd. (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-8748461-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| EP-1997809-B1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8722702-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722702-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8716498-B2 | 6-substituted phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20140121381-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-01 | — | — | US | disclosed |
| EP-2721022-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2721023-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2509975-B1 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2014-04-23 | — | — | EP | disclosed |
| WO-2014037480-A1 | 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-13 | — | — | WO | disclosed |
| WO-2014032801-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES | Grünenthal GmbH (DE) | 2014-03-06 | — | — | WO | disclosed |
| US-20140066426-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES | GRUENENTHAL GMBH (DE) | 2014-03-06 | — | — | US | disclosed |
| US-20140066426-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES | GRUENENTHAL GMBH (DE) | 2014-03-06 | — | — | US | disclosed |
| WO-2014032801-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES | Grünenthal GmbH (DE) | 2014-03-06 | — | — | WO | disclosed |
| US-20140066426-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES | GRUENENTHAL GMBH (DE) | 2014-03-06 | — | — | US | disclosed |
| EP-2688870-A1 | HETEROCYCLIC AMINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-29 | — | — | EP | disclosed |
| WO-2014006402-A1 | OREXIN RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2014-01-09 | — | — | WO | disclosed |
| US-20140005418-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-8604061-B2 | 2-aminooxazolines as TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8598086-B2 | 3-halo-(arly)-4-iminotetrahydropicolinates and their use as herbicides | DOW AGROSCIENCES, LLC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8586615-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-19 | — | — | US | disclosed |
| WO-2013169907-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-11-14 | — | — | WO | disclosed |
| US-8569522-B2 | 6-substituted phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130281690-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130274467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274468-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274469-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-17 | — | — | US | disclosed |
| WO-2013142307-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS (US) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013142307-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS (US) | 2013-09-26 | — | — | WO | disclosed |
| CN-102131794-B | 6-substituted phenoxy chroman carboxylic acid derivatives | ARRAY BIOPHARMA INC | 2013-09-25 | — | — | CN | disclosed |
| US-20130225617-A1 | INDOLES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| US-8518974-B2 | Isoxazolo-pyridine derivatives | Hoffmann-La Roche Inc (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518983-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-1997810-B1 | Indazoles, benzotriazoles and N-analogs thereof as p38 kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2440530-B1 | PROCESS FOR THE PREPARATION OF 6-(ARYL)-4-AMINOPICOLINATES | DOW AGROSCIENCES LLC (US) | 2013-07-24 | — | — | EP | disclosed |
| CN-103214471-A | Novel compound | MITSUBISHI TANABE PHARMA CORP | 2013-07-24 | — | — | CN | disclosed |
| WO-2013103973-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS (US) | 2013-07-11 | — | — | WO | disclosed |
| WO-2013103973-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS (US) | 2013-07-11 | — | — | WO | disclosed |
| US-20130178473-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178473-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8461169-B2 | Compounds modulating c-fms and/or c-kit activity | PLEXXIKON INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461169-B2 | Compounds modulating c-fms and/or c-kit activity | PLEXXIKON INC. (US) | 2013-06-11 | — | — | US | disclosed |
| WO-2013080141-A1 | Pyrazolopyrrolidine compounds | NOVARTIS AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| CN-103130745-A | Diaryl-piperazines compound and medical application thereof | INST PHARM & TOXICOLOGY AMMS | 2013-06-05 | — | — | CN | disclosed |
| EP-2593426-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2013064538-A1 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013064543-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013064543-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| US-8420646-B2 | Tricyclic tetrahydroquinoline antibacterial agents | PAH P&U LLC (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420646-B2 | Tricyclic tetrahydroquinoline antibacterial agents | PAH P&U LLC (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420646-B2 | Tricyclic tetrahydroquinoline antibacterial agents | PAH P&U LLC (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420655-B2 | Benzimidazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| US-8420655-B2 | Benzimidazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| US-8420655-B2 | Benzimidazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| EP-2575473-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8404700-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404700-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2013-03-26 | — | — | US | disclosed |
| WO-2013037960-A1 | EP1 RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-03-21 | — | — | WO | disclosed |
| US-20130072492-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME LLC | 2013-03-21 | — | — | US | disclosed |
| EP-2570125-A1 | Ep1 receptor ligands | Almirall, S.A. (ES) | 2013-03-20 | — | — | EP | disclosed |
| US-8399455-B2 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399455-B2 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399455-B2 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8394836-B2 | Indoles and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| EP-2334657-B1 | PIPERAZINE D3 AND 5-HT2A RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2013-03-06 | — | — | EP | disclosed |
| WO-2013024895-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-02-21 | — | — | WO | disclosed |
| US-8367838-B2 | Amines or amino alcohols as GLYT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2546254-A1 | Imidazo[4,5-C]pyridine compounds and methods of antiviral treatment | K.U.Leuven Research & Development (BE) | 2013-01-16 | — | — | EP | disclosed |
| EP-1651658-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20130005752-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| WO-2012177638-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012177635-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20120329788-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2039685-B1 | Heterobicyclic compounds as P38 inhibitors | ARRAY BIOPHARMA INC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8329727-B2 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120309756-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC | 2012-12-06 | — | — | US | disclosed |
| US-20120309756-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC | 2012-12-06 | — | — | US | disclosed |
| CN-101889010-B | Isoxazolo-pyridine derivatives | HOFFMANN LA ROCHE | 2012-12-05 | — | — | CN | disclosed |
| CN-102803219-A | Preparation method of 6- (aryl) -4-amino picolinate | DOW AGROSCIENCES LLC | 2012-11-28 | — | — | CN | disclosed |
| CN-102757426-A | Benzoisooxazolyl substituted thiazole compound, preparation method and application thereof | INST MEDICINAL BIOTECHNOLOGY | 2012-10-31 | — | — | CN | disclosed |
| EP-2514756-A1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-10-24 | — | — | EP | disclosed |
| EP-2509975-A1 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | Boehringer Ingelheim International GmbH (DE) | 2012-10-17 | — | — | EP | disclosed |
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-10-11 | — | — | US | disclosed |
| US-20120245172-A1 | HETEROCYCLIC AMINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-09-27 | — | — | US | disclosed |
| WO-2012126922-A1 | HETEROCYCLIC AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-27 | — | — | WO | disclosed |
| US-20120232033-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | KOLCZEWSKI SABINE (DE) | 2012-09-13 | — | — | US | disclosed |
| US-8252938-B2 | Process for the preparation of 6-(aryl)-4-aminopicolinates | DOW AGROSCIENCES, LLC. (US) | 2012-08-28 | — | — | US | disclosed |
| EP-2488491-A1 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS | F. Hoffmann-La Roche AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-20120196903-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | GALLEY GUIDO (DE) | 2012-08-02 | — | — | US | disclosed |
| EP-1706403-B9 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | LEUVEN K U RES & DEV (BE) | 2012-07-25 | — | — | EP | disclosed |
| US-20120184538-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-07-19 | — | — | US | disclosed |
| US-8222219-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| EP-1856097-B1 | PYRIDYL AND PHENYL SUBSTITUTED PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORP (US) | 2012-07-11 | — | — | EP | disclosed |
| CN-102548963-A | Novel N-substituted-pyrrolidines as inhibitors of MDM2-p53 interactions | HOFFMANN LA ROCHE | 2012-07-04 | — | — | CN | disclosed |
| US-8202984-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| EP-2440526-A1 | 3-HALO-6-(ARLY)-4-IMINOTETRAHYDROPICOLINATES AND THEIR USE AS HERBICIDES | Dow AgroSciences LLC (US) | 2012-04-18 | — | — | EP | disclosed |
| EP-2440530-A1 | PROCESS FOR THE PREPARATION OF 6-(ARYL)-4-AMINOPICOLINATES | Dow AgroSciences LLC (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| CN-101679309-B | Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound | KOWA CO | 2012-02-29 | — | — | CN | disclosed |
| EP-1706403-B1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | LEUVEN K U RES & DEV (BE) | 2012-02-08 | — | — | EP | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010257-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
| EP-2398558-A1 | AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | disclosed |
| US-20110301161-A1 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301161-A1 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301161-A1 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| US-8071604-B2 | Thio-substituted arylmethanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2011-12-06 | — | — | US | disclosed |
| WO-2011149921-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147951-A1 | CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS | PROSIDION LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
| US-8063234-B2 | Substituted 7-sulfanylmethyl-, 7-sulfinylmethyl- and 7-sulfonylmethylindoles and the use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-22 | — | — | US | disclosed |
| EP-1633740-B1 | 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-11-09 | — | — | EP | disclosed |
| CN-102232075-A | Aminopyrazole compounds | LILLY CO ELI | 2011-11-02 | — | — | CN | disclosed |
| US-20110230482-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY | PLEXXIKON INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230482-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY | PLEXXIKON INC. | 2011-09-22 | — | — | US | disclosed |
| EP-1740535-B1 | THIO-SUBSTITUTED ARYLMETHANESULFINYL DERIVATIVES | CEPHALON INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-8017607-B2 | N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions | HOFFMANN-LA ROCHE INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017641-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20110201564-A1 | SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | US | disclosed |
| CN-102159557-A | Piperazine d3 and 5-ht2a receptor modulators | HOFFMANN LA ROCHE | 2011-08-17 | — | — | CN | disclosed |
| US-7999113-B2 | Such as 1-(benzo[d][1,3]dioxol-6-yl)-n-(5-((2-chlorophenyl)(3-hydroxypyrrolidin-1-yl)methyl)thiazol-2-yl)cyclopropanecarboxamide; genetic disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-16 | — | — | US | disclosed |
| CN-1972909-B | Sulfur-substituted arylmethylsulfinyl derivatives | CEPHALON INC | 2011-07-27 | — | — | CN | disclosed |
| CN-102131794-A | 6-substituted phenoxy chroman carboxylic acid derivatives | ARRAY BIOPHARMA INC | 2011-07-20 | — | — | CN | disclosed |
| CN-102131776-A | Substituted 7-sulfanylmethyl, 7-sulfinylmethyl and 7-sulfonylmethyl indoles and use thereof | BAYER SCHERING PHARMA AG | 2011-07-20 | — | — | CN | disclosed |
| EP-2334657-A1 | PIPERAZINE D3 AND 5-HT2A RECEPTOR MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2011068821-A1 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011068821-A1 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-09 | — | — | WO | disclosed |
| EP-1912983-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2011-06-08 | — | — | EP | disclosed |
| EP-2327693-A1 | Indoles and their therapeutic use | Pulmagen Therapeutics (Asthma) Limited (GB) | 2011-06-01 | — | — | EP | disclosed |
| US-7943788-B2 | Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20110105463-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110092494-A1 | Tricyclic Tetrahydroquinoline Antibacterial Agents | PHARMACIA & UPJOHN COMPANY | 2011-04-21 | — | — | US | disclosed |
| US-20110092494-A1 | Tricyclic Tetrahydroquinoline Antibacterial Agents | PHARMACIA & UPJOHN COMPANY | 2011-04-21 | — | — | US | disclosed |
| US-20110092494-A1 | Tricyclic Tetrahydroquinoline Antibacterial Agents | PHARMACIA & UPJOHN COMPANY | 2011-04-21 | — | — | US | disclosed |
| WO-2011045257-A1 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | WO | disclosed |
| US-20110086854-A1 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS | BARTKOVITZ DAVID JOSEPH | 2011-04-14 | — | — | US | disclosed |
| EP-2307397-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | Array Biopharma, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| CN-102014914-A | 3H-[1,2,3]triazolo[4,5-D]pyrimidine compounds, their use as MTOR kinase and PI3 kinase inhibitors, and their syntheses | WYETH CORP | 2011-04-13 | — | — | CN | disclosed |
| EP-2300423-A1 | SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-03-30 | — | — | EP | disclosed |
| US-20110071175-A1 | Indoles and Their Therapeutic Use | GB005, INC. | 2011-03-24 | — | — | US | disclosed |
| US-7893075-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893075-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| CN-101970405-A | Indoles and their therapeutic use | PULMAGEN THERAPEUTICS ASTHMA L | 2011-02-09 | — | — | CN | disclosed |
| US-7868014-B2 | 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mGluR3 antagonists | ELI LILLY AND COMPANY (US) | 2011-01-11 | — | — | US | disclosed |
| US-7863444-B2 | 4-aminopyrrolopyrimidines as kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-01-04 | — | — | US | disclosed |
| US-7858630-B2 | D3 and 5-HT2A receptor modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| WO-2010144380-A1 | PROCESS FOR THE PREPARATION OF 6-(ARYL)-4-AMINOPICOLINATES | DOW AGROSCIENCES LLC (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010144379-A1 | 3-HALO-(ARLY)-4-IMINOTETRAHYDROPICOLINATES AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20100311981-A1 | PROCESS FOR THE PREPARATION OF 6-(ARYL)-4-AMINOPICOLINATES | DOW AGROSCIENCES LLC (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311594-A1 | 3-HALO-(ARLY)-4-IMINOTETRAHYDROPICOLINATES AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2010-12-09 | — | — | US | disclosed |
| EP-2252296-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | Wyeth LLC (US) | 2010-11-24 | — | — | EP | disclosed |
| CN-101889010-A | Isoxazolo-pyridine derivatives | HOFFMANN LA ROCHE | 2010-11-17 | — | — | CN | disclosed |
| EP-2229358-A1 | INDOLES AND THEIR THERAPEUTIC USE | Pulmagen Therapeutics (Asthma) Limited (GB) | 2010-09-22 | — | — | EP | disclosed |
| US-7799782-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20100234356-A1 | COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234356-A1 | COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234356-A1 | COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| EP-2227467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| WO-2010094659-A1 | AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
| US-20100210592-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | disclosed |
| US-7776862-B2 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1551849-B1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN CO LLC (US) | 2010-07-14 | — | — | EP | disclosed |
| CN-101759645-A | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC | 2010-06-30 | — | — | CN | disclosed |
| US-7741345-B2 | AZA-peptide protease inhibitors | GILEAD SCIENCES, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20100120858-A1 | Piperidine Derivatives | PFIZER INC. | 2010-05-13 | — | — | US | disclosed |
| US-20100120864-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | GALLEY GUIDO | 2010-05-13 | — | — | US | disclosed |
| US-20100105744-A1 | SUBSTITUTED 7-SULFANYLMETHYL-, 7-SULFINYLMETHYL- AND 7-SULFONYLMETHYLINDOLES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-29 | — | — | US | disclosed |
| US-20100075983-A1 | D3 AND 5-HT2A RECEPTOR MODULATORS | HOFFMANN-LA ROCHE, INC. | 2010-03-25 | — | — | US | disclosed |
| WO-2010031735-A1 | PIPERAZINE D3 AND 5-HT2A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| CN-101679309-A | Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound | KOWA CO | 2010-03-24 | — | — | CN | disclosed |
| EP-2161273-A1 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | K.U.Leuven Research & Development (BE) | 2010-03-10 | — | — | EP | disclosed |
| US-7659271-B2 | Pyrimidine compound having dibenzylamine structure and medicament comprising the same | KOWA COMPANY, LTD. (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-02-04 | — | — | US | disclosed |
| EP-2149563-A1 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | Kowa Company. Ltd. (JP) | 2010-02-03 | — | — | EP | disclosed |
| US-20100022524-A1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY | 2010-01-28 | — | — | US | disclosed |
| US-7648998-B2 | 5-((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine; hepatitis-C-virus | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2010-01-19 | — | — | US | disclosed |
| CN-100579976-C | p38 inhibitors and methods of their use | ARRAY BIOPHARMA INC | 2010-01-13 | — | — | CN | disclosed |
| WO-2009156072-A1 | SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158426-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| US-7635698-B2 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635698-B2 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635698-B2 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| EP-1805165-B1 | 1-(HETERO)ARYL-3-AMINO-PYRROLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-12-16 | — | — | EP | disclosed |
| CN-101600700-A | Novel 2-aminooxazolines as TAAR1 ligands for CNS disorders | HOFFMANN LA ROCHE (CH) | 2009-12-09 | — | — | CN | disclosed |
| EP-2114906-A1 | NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | F. Hoffmann-Roche AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-7608639-B2 | Phenoxyether derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-27 | — | — | US | disclosed |
| US-7605157-B2 | Tricyclic tetrahydroquinoline antibacterial agents | PHARMACIA & UPJOHN COMPANY LLC (US) | 2009-10-20 | — | — | US | disclosed |
| CN-101538267-A | Imidazo [4, 5-c ] pyridine compounds and methods of antiviral treatment | LEUVEN K U RES & DEV GILEAD SC (BE) | 2009-09-23 | — | — | CN | disclosed |
| US-7592357-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| CN-101506164-A | Piperidine derivatives | PFIZER PROD INC (US) | 2009-08-12 | — | — | CN | disclosed |
| WO-2009091788-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090182142-A1 | Aromatic Compound | FURUKUBO SHIGERU | 2009-07-16 | — | — | US | disclosed |
| US-20090182142-A1 | Aromatic Compound | FURUKUBO SHIGERU | 2009-07-16 | — | — | US | disclosed |
| US-20090182142-A1 | Aromatic Compound | FURUKUBO SHIGERU | 2009-07-16 | — | — | US | disclosed |
| US-20090181963-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-16 | — | — | US | disclosed |
| US-7560467-B2 | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| WO-2009077728-A1 | INDOLES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009071476-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| US-20090149459-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-06-11 | — | — | US | disclosed |
| EP-2066630-A1 | PIPERIDINE DERIVATIVES | Pfizer Products Incorporated (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | ROCHE PALO ALTO LLC | 2009-06-04 | — | — | US | disclosed |
| US-20090143422-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090136596-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-05-28 | — | — | US | disclosed |
| EP-1718638-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-2049547-A2 | AZA-PEPTIDE PROTEASE INHIBITORS | Gilead Sciences, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| US-7521447-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20090099096-A1 | AZA-peptide protease inhibitors | GILEAD SCIENCES, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090082352-A1 | N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) | KOWA COMPANY, LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-2039685-A2 | Heterobicyclic compounds as P38 inhibitors | Array Biopharma, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| US-20090018143-A1 | Thio-substituted arylmethanesulfinyl derivatives | CEPHALON, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| CN-101318943-A | Substituted piperazine compounds, preparation method and application thereof, and pharmaceutical composition containing compounds | SHANGHAI INST MATERIA MEDICA (CN) | 2008-12-10 | — | — | CN | disclosed |
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | ELI LILLY AND COMPANY (US) | 2008-12-04 | — | — | US | disclosed |
| EP-1997809-A2 | Indazole, benzoxazole and pyrazolopyridine derivatives for medical use | Array Biopharma Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997810-A2 | Indazole, benzoxazole and pyrazolopyridine derivatives for medical use | Array Biopharma Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997811-A2 | Indazole, benzoxazole and pyrazolopyridine derivatives as P38 kinase inhibitors | Array Biopharma Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1633740-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-23 | — | — | US | disclosed |
| CN-101287732-A | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMA (US) | 2008-10-15 | — | — | CN | disclosed |
| WO-2004078116-A9 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008099020-A1 | 1,1-DIOXO-1-THIA-5,10-DIAZADIBENZOCYCLOHEPTENES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-21 | — | — | WO | disclosed |
| EP-1956009-A1 | AROMATIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-1956009-A1 | AROMATIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008092785-A1 | NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | WO | disclosed |
| EP-1567489-B1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20080161371-A1 | Modulators of cystic fibrosis transmembrane conductance regulator | FIRST-CITIZENS BANK & TRUST COMPANY | 2008-07-03 | — | — | US | disclosed |
| CN-101213185-A | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonistic activity | SCHERING CORP (US) | 2008-07-02 | — | — | CN | disclosed |
| US-20080125427-A1 | Novel Inhibitors of Rho-Kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125427-A1 | Novel Inhibitors of Rho-Kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125427-A1 | Novel Inhibitors of Rho-Kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-29 | — | — | US | disclosed |
| WO-2008064265-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008064255-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| EP-1912983-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals, Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20080058384-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2008-03-06 | — | — | US | disclosed |
| WO-2008023258-A1 | PIPERIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008011116-A2 | AZA-PEPTIDE PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| CN-101094846-A | 1- (hetero) aryl-3-amino-pyrrolidine derivatives as MGLUR3 receptor antagonists | LILLY CO ELI (US) | 2007-12-26 | — | — | CN | disclosed |
| US-7297817-B2 | Thio-substituted arylmethanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2007-11-20 | — | — | US | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| US-20070161630-A1 | Tricyclic tetrahydroquinoline antibacterial agents | ZOETIS SERVICES LLC | 2007-07-12 | — | — | US | disclosed |
| EP-1805165-A1 | 1-(HETERO)ARYL-3-AMINO-PYROLLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1791807-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | Pfizer Products Incorporated (US) | 2007-06-06 | — | — | EP | disclosed |
| CN-1972909-A | Sulfur-substituted arylmethylsulfinyl derivatives | CEPHALON INC (US) | 2007-05-30 | — | — | CN | disclosed |
| EP-1606283-A4 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20070099944-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-03 | — | — | US | disclosed |
| US-7208490-B2 | Tricyclic tetrahydroquinoline antibacterial agents | PHARMACIA & UPJOHN COMPANY LLC (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1756092-A1 | NOVEL INHIBITORS OF RHO-KINASES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2007021982-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037812-A1 | Such as 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid; peroxisome proliferator activated receptor (PPAR); syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis | ELI LILLY AND COMPANY (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070021611-A1 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| CN-1902198-A | Imidazo [4, 5-c ] pyridine compounds and methods of antiviral treatment | K U LEUVEN RES & DEV GERHARD P (BE) | 2007-01-24 | — | — | CN | disclosed |
| EP-1740535-A1 | THIO-SUBSTITUTED METHANESULFINYL DERIVATIVES | CEPHALON, INC. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060257987-A1 | Ppar modulators | ELI LILLY AND COMPANY | 2006-11-16 | — | — | US | disclosed |
| US-7135575-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1718638-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-08 | — | — | EP | disclosed |
| US-7119203-B2 | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1706403-A2 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | K.U.Leuven Research & Development (BE) | 2006-10-04 | — | — | EP | disclosed |
| CN-1842516-A | Amide compounds and method for controlling plant diseases using the same | SUMITOMO CHEMICAL CO (JP) | 2006-10-04 | — | — | CN | disclosed |
| CN-1829729-A | Novel compounds | TANABE SEIYAKU CO (JP) | 2006-09-06 | — | — | CN | disclosed |
| US-20060189628-A1 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1689743-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | GLAXO GROUP LIMITED (GB) | 2006-07-27 | — | — | US | disclosed |
| WO-2006071958-A1 | COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-07-06 | — | — | WO | disclosed |
| EP-1675814-A1 | PHENOXYETHER DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20060122065-A1 | Amide compound and method of controlling plant disease with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-06-08 | — | — | US | disclosed |
| US-20060122064-A1 | Amides and method for plant diseases control with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-06-08 | — | — | US | disclosed |
| CN-1784396-A | p38 inhibitors and methods of their use | ARRAY BIOPHARMA INC (US) | 2006-06-07 | — | — | CN | disclosed |
| EP-1660428-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1651658-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2006-05-03 | — | — | EP | disclosed |
| WO-2006044454-A1 | 1-(HETERO)ARYL-3-AMINO-PYROLLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006044187-A1 | A METHOD FOR PREPARING ACETAL-CONTAINING COMPOSITIONS AND RELATED COMPOSITIONS AND ARTICLES | MILLIKEN & COMPANY (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060079720-A1 | Method for preparing acetal-containing compositions | MILLIKEN & COMPANY | 2006-04-13 | — | — | US | disclosed |
| EP-1640360-A1 | AMIDES AND METHOD FOR PLANT DISEASE CONTROL WITH THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-03-29 | — | — | EP | disclosed |
| WO-2006027684-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
| EP-1633740-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2006-03-15 | — | — | EP | disclosed |
| CN-1729159-A | Amide compounds and methods for controlling plant diseases | SUMITOMO CHEMICAL CO (JP) | 2006-02-01 | — | — | CN | disclosed |
| WO-2006009889-A1 | NOVEL INHIBITORS OF RHO-KINASES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006009889-A1 | NOVEL INHIBITORS OF RHO-KINASES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-01-26 | — | — | WO | disclosed |
| EP-1606283-A2 | P38 INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050256133-A1 | Thio-substituted arylmethanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2005-11-17 | — | — | US | disclosed |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| WO-2005100310-A1 | THIO-SUBSTITUTED ARYLMETHANESULFINYL DERIVATIVES | CEPHALON INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050233988-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-20 | — | — | US | disclosed |
| US-20050222198-A1 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | K.U. LEUVEN RESEARCH & DEVELOPMENT, GERHARD PUERSTINGER AND GILEAD SCIENCES, INC. | 2005-10-06 | — | — | US | disclosed |
| US-20050209278-A1 | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2005-09-22 | — | — | US | disclosed |
| EP-1577290-A1 | AMIDE COMPOUND AND METHOD OF CONTROLLING PLANT DISEASE WITH THE SAME | Sumitomo Chemical Company, Limited (JP) | 2005-09-21 | — | — | EP | disclosed |
| WO-2005082890-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-1567489-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2005063744-A2 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2005-07-14 | — | — | WO | disclosed |
| EP-1551849-A1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company LLC (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2005044008-A2 | 2 -AMINOTHIOPHENE COMPOUNDS AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005042521-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005037763-A1 | PHENOXYETHER DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005019151-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005012326-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-10 | — | — | WO | disclosed |
| EP-1501827-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACID AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20050009838-A1 | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
| WO-2004112719-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
| EP-1425015-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6825208-B2 | SELECTIVE INHIBITORS OF SERINE PROTEASE ENZYMES, ESPECIALLY FACTOR VIIA; MODULATION OF THE COAGULATION CASCADE. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-30 | — | — | US | disclosed |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. | 2004-09-30 | — | — | US | disclosed |
| US-20040180896-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA, INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004078116-A2 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040176325-A1 | P38 MAP kinase inhibitors comprising indazole derivatives; antiinflammatory and antiproliferative agents; autoimmune, bone, and neurodegenerative disorders; viricides, infections | ARRAY BIOPHARMA INC. | 2004-09-09 | — | — | US | disclosed |
| US-20040162279-A1 | Tricyclic tetrahydroquinoline antibacterial agents | ZOETIS SERVICES LLC | 2004-08-19 | — | — | US | disclosed |
| WO-2004052851-A1 | PYRROLYDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-06-24 | — | — | WO | disclosed |
| EP-1425015-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | disclosed |
| WO-2004031195-A1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-04-15 | — | — | WO | disclosed |
| CN-1139580-C | Substituted benzylamines and their use for the treatment of depression | ��˹��ŵ�� | 2004-02-25 | — | — | CN | disclosed |
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-12-04 | — | — | US | disclosed |
| WO-2003091247-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-11-06 | — | — | WO | disclosed |
| US-6583180-B2 | Antidiabetic agents | ABBOTT LABORATORIES | 2003-06-24 | — | — | US | disclosed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| US-6518268-B1 | Telomerase inhibitors and methods of their use | GERON CORPORATION | 2003-02-11 | — | — | US | disclosed |
| US-20020156311-A1 | Glucocorticoid receptor modulators | KARO BIO AB (SE) | 2002-10-24 | — | — | US | disclosed |
| CN-1321153-A | telomerase inhibitors and methods of use thereof | GERON CORP (US) | 2001-11-07 | — | — | CN | disclosed |
| WO-2001002377-A9 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORP (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-1109796-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | Geron Corporation (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6242634-B1 | OF HERBICIDES, HALOPHENYL COMPOUNDS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-06-05 | — | — | US | disclosed |
| EP-1101752-A2 | Process for the preparation of halogenated benzyl alcohols | Clariant GmbH (DE) | 2001-05-23 | — | — | EP | disclosed |
| WO-2001002377-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
| US-6100257-A | 2-HALOALKYL,3-(HALOALKYL, ALKENYL, OR ALKYNYL),5-(SUBSTITUTED PHENYL OR HETEROCYCLE),6-ALKYL-PYRIMIDIN-4-ONE COMPOUNDS OF GIVEN STRUCTURE; USE AS HERBICIDES | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2000-08-08 | — | — | US | disclosed |
| US-6054412-A | AGRICULTURE, HORTICULTURE | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-25 | — | — | US | disclosed |
| US-6015774-A | Pyrazin-2-one derivatives, their use, and intermediates for their production | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-01-18 | — | — | US | disclosed |
| CN-1219169-A | Substituted benzylamines and their use for the treatment of depression | AKZO NOBEL NV (NL) | 1999-06-09 | — | — | CN | disclosed |
| EP-0265854-B2 | Process for preparing fluorobenzaldehydes | CLARIANT GMBH (DE) | 1999-03-24 | — | — | EP | disclosed |
| US-5866723-A | INTERMEDIATES FOR AN ACTIVE CLASS OF ARYL-HALOALKYLPYRAZOLE AND ARYL ALKYLSULFONYLPYRAZOLE HERBICIDES. | MONSANTO COMPANY (US) | 1999-02-02 | — | — | US | disclosed |
| CN-1198742-A | Pyrimidin-4-one derivatives, their use as herbicides, intermediates for their production and process for producing these compounds | SUMITOMO CHEMICAL CO (JP) | 1998-11-11 | — | — | CN | disclosed |
| EP-0862558-A1 | SUBSTITUTED 4,5-DI(TRIFLUOROMETHYL)PYRAZOLES AND THEIR USE AS HERBICIDES AND FOR DESICCATING/DEFOLIATING PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-09 | — | — | EP | disclosed |
| EP-0850229-A1 | PYRIMIDIN-4-ONE DERIVATIVES, THEIR USE AS HERBICIDES, INTERMEDIATES FOR THEIR PRODUCTION AND PROCESSES FOR PRODUCING THESE COMPOUNDS | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1998-07-01 | — | — | EP | disclosed |
| EP-0653412-B1 | Process for preparing 4,5-difluorobenzaldehydes | BAYER AG (DE) | 1998-01-21 | — | — | EP | disclosed |
| EP-0811008-A1 | BICYCLIC BENZAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | American Cyanamid Company (US) | 1997-12-10 | — | — | EP | disclosed |
| CN-1159180-A | Benzoyl derivatives and synthesis thereof | MONSANTO CO (US) | 1997-09-10 | — | — | CN | disclosed |
| US-5654490-A | LEWIS ACID CATALYZED ALKYLATION OF A PHENYL FLUORIDE WITH A HALOGENATED ALKYL ETHER, HYDROLYSIS TO FORM A 2-FLUORO-BENZALDEHYDE | MONSANTO COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0772580-A1 | BENZOYL DERIVATIVES AND SYNTHESIS THEREOF | MONSANTO COMPANY (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1997015559-A1 | SUBSTITUTED 4,5-DI(TRIFLUOROMETHYL)PYRAZOLES AND THEIR USE AS HERBICIDES AND FOR DESICCATING/DEFOLIATING PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | disclosed |
| WO-1997006150-A1 | PYRIMIDIN-4-ONE DERIVATIVES, THEIR USE AS HERBICIDES, INTERMEDIATES FOR THEIR PRODUCTION AND PROCESSES FOR PRODUCING THESE COMPOUNDS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-02-20 | — | — | WO | disclosed |
| US-5532416-A | ACYLATION OF FLUORO HALO ALKYLBENZOYL COMPOUNDS FOR HERBICIDES | MONSANTO COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| US-5502073-A | INSECTICIDES OR ANTHELMINTICS | THE WELLCOME FOUNDATION (GB) | 1996-03-26 | — | — | US | disclosed |
| US-5489715-A | Process for preparing 4,5-difluorobenzaldehydes | BAYER AKTIENGESELLSCHAFT (DE) | 1996-02-06 | — | — | US | disclosed |
| WO-1996002486-A1 | BENZOYL DERIVATIVES AND SYNTHESIS THEREOF | MONSANTO COMPANY (US) | 1996-02-01 | — | — | WO | disclosed |
| EP-0653412-A1 | Process for preparing 4,5-difluorobenzaldehydes | BAYER AG (DE) | 1995-05-17 | — | — | EP | disclosed |
| CN-1025677-C | Novel heterocyclic pesticidal compounds | WELLCOME FOUND (GB) | 1994-08-17 | — | — | CN | disclosed |
| US-5227531-A | Process for the preparation of fluorobenzaldehydes | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-07-13 | — | — | US | disclosed |
| EP-0289942-B1 | PROCESS FOR PRODUCING FLUOROBENZALDEHYDES | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 1993-07-07 | — | — | EP | disclosed |
| EP-0294229-B1 | NOVEL HETEROCYCLIC PESTICIDAL COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-12-02 | — | — | EP | disclosed |
| EP-0351644-B1 | PROCESS FOR THE PREPARATION OF FLUOROBENZENES | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-06-10 | — | — | EP | disclosed |
| CN-1016868-B | Process for preparing 5-aralkyl-4-alkoxy-2 (5H) -furanone | SCHWABE WILLMAR GMBH & CO (DE) | 1992-06-03 | — | — | CN | disclosed |
| EP-0247320-B1 | 5-ARYLALKYL-4-ALKOXY-2(5H)-FURANONES, INTERMEDIATES AND PROCESS FOR THEIR PREPARATION AS WELL AS THEIR APPLICATION AS THERAPEUTICALLY ACTIVE INGREDIENTS | SCHWABE WILLMAR GMBH & CO (DE) | 1990-12-27 | — | — | EP | disclosed |
| US-4937395-A | Process for the preparation of fluorobenzenes | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-06-26 | — | — | US | disclosed |
| EP-0351644-A1 | Process for the preparation of fluorobenzenes | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-01-24 | — | — | EP | disclosed |
| US-4855320-A | ANTICONVULSANTS, ANTIEPILEPTICS | DR. WILLMAR SCHWABE GMBH & COMPANY (DE) | 1989-08-08 | — | — | US | disclosed |
| US-4845304-A | CATALYTIC FLUORINATION OF HALOBENZALDEHYDE WITH POTASSIUM FLUORIDE | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1989-07-04 | — | — | US | disclosed |
| CN-1030236-A | NOVEL HETEROCYCLIC PESTICIDAL COMPOUNDS | WELLCOME FOUND (GB) | 1989-01-11 | — | — | CN | disclosed |
| EP-0294229-A2 | Novel heterocyclic pesticidal compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-12-07 | — | — | EP | disclosed |
| EP-0289942-A2 | Process for producing fluorobenzaldehydes | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 1988-11-09 | — | — | EP | disclosed |
| EP-0265854-A1 | Process for preparing fluorobenzaldehydes | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-05-04 | — | — | EP | disclosed |
| EP-0247320-A2 | 5-Arylalkyl-4-alkoxy-2(5H)-furanones, intermediates and process for their preparation as well as their application as therapeutically active ingredients | Dr. Willmar Schwabe GmbH & Co. (DE) | 1987-12-02 | — | — | EP | disclosed |
| US-3982020-A | Substituted benzylidene hydrazines for treating hyperglycemia, obesity and inflammation | SANDOZ, INC. (US) | 1976-09-21 | — | — | US | disclosed |
| US-3982020-A | Substituted benzylidene hydrazines for treating hyperglycemia, obesity and inflammation | SANDOZ, INC. (US) | 1976-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | TFPI, TFPI2, SERPINC1 | TDP1 1311/4885ERN1 1774/4885HSD17B10 2007/4885 |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | TDP1 4744/4885ERN1 2062/4885HSD17B10 549/4885 |
| US-20180134674-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | TDP1 3765/4885ERN1 3681/4885HSD17B10 4690/4885 |
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | GABRA5, GABRA1, CHRNA5 | TDP1 2147/4885ERN1 3593/4885HSD17B10 1849/4885 |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | TDP1 161/4885ERN1 1112/4885HSD17B10 2485/4885 |
| US-20200071280-A1 | PYRIMIDINE DERIVATIVE | CXCR1, PTGS1, P2RY1 | TDP1 529/4885ERN1 261/4885HSD17B10 3755/4885 |
| US-20170044155-A1 | Geminal Substituted Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | CHRNA7, CHRNA5, CHRNA6 | TDP1 2381/4885ERN1 4726/4885HSD17B10 2741/4885 |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | TDP1 2664/4885ERN1 3683/4885HSD17B10 1435/4885 |
| US-12466840-B2 | Small molecule inhibitors of KRAS proteins | KRAS, NRAS, HRAS | TDP1 3689/4885ERN1 2221/4885HSD17B10 4571/4885 |
| US-20120245172-A1 | HETEROCYCLIC AMINE DERIVATIVES | TAAR1, TAAR5, MTNR1A | TDP1 1074/4885ERN1 3307/4885HSD17B10 1122/4885 |
| US-20050233988-A1 | Novel compounds | CYP1B1, CYP4B1, CYP2B6 | TDP1 4514/4885ERN1 2429/4885HSD17B10 489/4885 |
| US-11530189-B2 | Carbamate compounds and methods of making and using same | ABHD6, ABHD16A, RABL6 | TDP1 597/4885ERN1 3640/4885HSD17B10 2149/4885 |
| US-20180201609-A1 | INDAZOLE AND AZAINDAZOLE COMPOUNDS AS IRAK-4 INHIBITORS | IRAK4, IRAK3, IRAK2 | TDP1 937/4885ERN1 583/4885HSD17B10 2680/4885 |
| US-10751335-B2 | Signaling-biased mu opioid receptor agonists | OPRK1, OPRM1, OPRD1 | TDP1 4671/4885ERN1 2605/4885HSD17B10 3736/4885 |
| US-20160237078-A9 | NOVEL 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | CYP2B6, HAVCR2, CYP2D6 | TDP1 1566/4885ERN1 2687/4885HSD17B10 974/4885 |
| US-20220127227-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | GPR17, GPR18, GPR27 | TDP1 2989/4885ERN1 4584/4885HSD17B10 758/4885 |
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | TDP1 2792/4885ERN1 3756/4885HSD17B10 1362/4885 |
| US-20170121320-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | TDP1 4441/4885ERN1 4179/4885HSD17B10 2075/4885 |
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | TDP1 1627/4885ERN1 1159/4885HSD17B10 527/4885 |
| US-10710967-B2 | Pyrimidine derivative | CXCR1, PTGS1, P2RY1 | TDP1 529/4885ERN1 261/4885HSD17B10 3755/4885 |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, FAAH, FAAH2 | TDP1 4025/4885ERN1 3396/4885HSD17B10 1188/4885 |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | TDP1 1362/4885ERN1 1598/4885HSD17B10 3855/4885 |
| US-20230150942-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TP53, HCCS, CFTR | TDP1 2795/4885ERN1 4181/4885HSD17B10 2167/4885 |
| US-20150031687-A1 | Novel 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | CYP2B6, HAVCR2, CYP2D6 | TDP1 1566/4885ERN1 2687/4885HSD17B10 974/4885 |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | TDP1 3106/4885ERN1 1077/4885HSD17B10 1520/4885 |
| US-20100105744-A1 | SUBSTITUTED 7-SULFANYLMETHYL-, 7-SULFINYLMETHYL- AND 7-SULFONYLMETHYLINDOLES AND THE USE THEREOF | STS, HTR7, PCSK7 | TDP1 2876/4885ERN1 3793/4885HSD17B10 1220/4885 |
| US-20050256133-A1 | Thio-substituted arylmethanesulfinyl derivatives | HTR1A, SLC6A3, HTR3B | TDP1 1621/4885ERN1 4555/4885HSD17B10 997/4885 |
| US-20060122065-A1 | Amide compound and method of controlling plant disease with the same | CBR3, C5, CLN6 | TDP1 4768/4885ERN1 217/4885HSD17B10 795/4885 |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | NR5A2, NR5A1, GPER1 | TDP1 4796/4885ERN1 3690/4885HSD17B10 477/4885 |
| US-20080125427-A1 | Novel Inhibitors of Rho-Kinases | ROCK1, ARHGDIB, ARHGDIA | TDP1 1254/4885ERN1 552/4885HSD17B10 4054/4885 |
| US-11345662-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | GPR17, GPR18, GPR27 | TDP1 2989/4885ERN1 4584/4885HSD17B10 758/4885 |
| US-20140243365-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | TDP1 3089/4885ERN1 3757/4885HSD17B10 3930/4885 |
| US-20170174675-A9 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SCNN1G, SCNN1B | TDP1 4739/4885ERN1 3282/4885HSD17B10 2257/4885 |
| US-11426397-B2 | Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 | GPR6, GPR3, GPR68 | TDP1 4539/4885ERN1 4660/4885HSD17B10 3816/4885 |
| US-20200223830-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | TDP1 1362/4885ERN1 1598/4885HSD17B10 3855/4885 |
| US-10781211-B2 | Spirocycle compounds and methods of making and using same | ABHD6, ABHD16A, ACSL6 | TDP1 4302/4885ERN1 2574/4885HSD17B10 237/4885 |
| US-10463753-B2 | Radiolabeled monoacylglycerol lipase occupancy probe | MGLL, LPL, PNLIP | TDP1 2556/4885ERN1 3032/4885HSD17B10 299/4885 |
| US-20090143422-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | MAPKAPK2, MAPK1, MAPK8 | TDP1 793/4885ERN1 297/4885HSD17B10 3003/4885 |
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | TDP1 505/4885ERN1 792/4885HSD17B10 345/4885 |
| US-20190071435-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GLP1R, GCGR | TDP1 4440/4885ERN1 3278/4885HSD17B10 1592/4885 |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | TDP1 84/4885ERN1 1469/4885HSD17B10 2805/4885 |
| US-20140350010-A1 | Pyrazolopyrrolidine Compounds | MDM4, MDM2, TP53 | TDP1 53/4885ERN1 2565/4885HSD17B10 3676/4885 |
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | JAK2, JAK1, JAK3 | TDP1 1536/4885ERN1 514/4885HSD17B10 2849/4885 |
| US-11021453-B2 | Carbamate compounds and methods of making and using same | ABHD6, ABHD16A, RABL6 | TDP1 624/4885ERN1 3553/4885HSD17B10 2086/4885 |
| US-20130225617-A1 | INDOLES AND THEIR THERAPEUTIC USE | IDO2, IDO1, RORB | TDP1 4427/4885ERN1 3615/4885HSD17B10 1342/4885 |
| US-20180305366-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A1, GUCY1A2, PDE2A | TDP1 419/4885ERN1 1959/4885HSD17B10 4104/4885 |
| US-10172866-B2 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | RORA, RORB, RORC | TDP1 4055/4885ERN1 2773/4885HSD17B10 439/4885 |
| US-20110301161-A1 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTC4S, LTB4R, LTB4R2 | TDP1 4224/4885ERN1 2877/4885HSD17B10 1069/4885 |
| US-11560356-B2 | Compounds and compositions for the treatment of cancer | TP53, HCCS, CFTR | TDP1 2795/4885ERN1 4181/4885HSD17B10 2167/4885 |
| US-11897851-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | TDP1 2664/4885ERN1 3683/4885HSD17B10 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.